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In November 2007, I enrolled in PhD three years course in Pharmaceutical 
Sciences at the Department of Pharmaceutical Sciences of Salerno University 
under the supervision of Prof. Raffaele Riccio. 
My research activity was mainly focused onto the development of mass 
spectrometry-based chemical proteomics. These approaches were successfully 
applied to the interactome characterization of three bioactive marine 
metabolites, Petrosaspongiolide M, Bolinaquinone and Perthamide C. The 
entire work was carried out under the direct supervision of Prof. A. Casapullo 
and Dr. Maria Chiara Monti.  
Since our methodology required some biochemical efforts, I also joined forces 
of Dr. Alessandra Tosco and Dr. Bianca Fontanella from the biochemistry 
section of our Department.  
Furthermore, to improve my knowledge on the quantitative features of 
chemical proteomics, I moved to the Department of Biomolecular Mass 
Spectrometry and Proteomic Group of the Utrecht University in 2009. There, 
my research was carried out under the supervision of Prof. Albert J.R. Heck 
and Dr. Arjen Scholten and was mainly focused on the application of targeted 
quantitative chemical proteomics to uncover spatial reorganization of cAMP 
and cGMP signaling scaffolds in collagen stimulated platelets. 
In addition to PhD course activities, I was involved in different side projects, 
mainly regarding the molecular recognition processes of small marine 
metabolites with phospholipase A2 and tau protein.  
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The emerging field of mass spectrometry-based chemical proteomics provides 
a powerful instrument in the target discovery of bioactive small-molecules, 
such as drugs or natural products
[1]
. The identification of their macromolecular 
targets is required for a comprehensive understanding of their bio-
pharmacological role and for unraveling their mechanism of action
[1, 2]
. 
Indeed, the target discovery of bioactive molecules endowed with intriguing 
pharmacological profiles is one of the main issues in the field of 
pharmaceutical sciences, since this is necessary for a rational development of 
potential drugs. Nevertheless, several bioactive compounds have been mainly 
evaluated for their pharmacological effects, whereas the exact mechanism of 
action at molecular level still remains unknown
[3, 4]
.  
Moreover, a complementary point of view about the effect of a small bioactive 
molecule on a cellular system can be given by label-based quantitative 
proteomic analysis
[5]
. Indeed, the identification of biologically relevant 
changes in the expression of proteins in a cell, after a treatment with a 
bioactive compound, could help to understand the exact mechanism of action 
of such active compound. 
Here, we report the application of chemical proteomics to the analysis of the 
cellular interactome of three marine bioactive metabolites, all showing an 
intriguing anti-inflammatory pharmacological profile, and the application of 
quantitative chemical proteomics to the platelets activation mechanism by 





 and Perthamide C 
(PRT)
[12]
 target discovery. Thus, these molecules were immobilized onto 






modified beads were then used as baits for fishing the potential partners of the 
bioactive compounds in macrophages cell lysate. The application of such 
technique allowed us to identify 20S proteasome, clathrin  and endoplasmin 
(GRP94) as main partners of PM, BLQ and PRT, respectively.  
Then, in vitro and in cell fluorescence assays were developed to assess the 
effect of PM onto the 20S proteasome enzymatic system, allowing us to 
measure the inhibition potency of this sesterterpene on the different proteolytic 
sites of the proteasome machinery.  
The BLQ ability to modulate clathrin mediated endocytosis has been assessed 
through cytofluorimetric and microscopy analysis, suggesting a new 
application of BLQ as biotechnological tool in the modulation of trafficking 
pathways. 
SPR technology has been employed to prove the ability of PRT to interact 
with GRP94 and Hsp90, opening the way to further investigations on the role 
of PRT in the modulation of heat shock protein functions. 
Finally, we report the application of quantitative chemical proteomics to 
discover the effect of collagen on platelet activation. Since cAMP and cGMP 
plays a key role in platelet activation
[13]
, we combined quantitative chemical 
proteomics approach with the specific enrichment of cAMP/cGMP signaling 
nodes
[14]
, to investigate how PKA but also cGMP-dependent protein kinases 
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1.1 Target discovery and “omics” sciences 
 
One of the main purpose of pharmaceutical companies is the finding of new 
druggable targets, whereas the exact targets of some drugs, actually in clinical 
or under development, remain unknown. Besides, a lot of compounds show a 
jumbled pharmacological profile with a modulation of several targets, 
providing advanced therapeutic effects, particularly for complex diseases . The 
simplified “one molecule, one target” concept seems to be by now out-of-
date
[1]
. The main advantage for a drug hitting more than one target is the 
possible application in a plethora of diseases, even if the multi-target 
interaction could also lead to harmful side effects, reducing the potency and 
efficiency of the drugs. Thus, the only way to better understand the  poly-
pharmacological activities and toxicity of a drug is the comprehensive 
characterization of its target interaction profile inside a complex mixture, such 
as the cellular environment
[2]
.  
The identification of a drug interactome followed by biological assays for the 
measure of its activity against the identified target proteins, is actually one of 
the key processes in the drug development process. Several approaches mainly 
based on protein array and reverse docking have been developed to reach this 
goal even if gaining only a partial coverage of the full interactome,  due to the 
absence of a biological context. 
Recent developments in analytical methods, mainly in mass spectrometry and 
liquid chromatography, have had an important impact in the field of target 
discovery. In particular, mass spectrometry-based chemical proteomics has 
been emerging as a powerful tool to a comprehensive characterization of a 
drug interactome under physiological relevant conditions. Moreover, such 
method enables the analysis of the drug mechanism of action, in the context of 









1.2 Chemical proteomics 
 
Chemical proteomics is considered a combination of affinity purification  and 
mass spectrometric identification of a set of proteins targeted (or captured) by 
a small molecule. It is a multidisciplinary technique, involving different 
research areas such as biochemistry, cell biology, organic synthesis and mass 
spectrometry. This technique allows the analysis of all potential targets of a 
molecule in a single experiment, leading to a complete and selective target 
mapping  of a drug candidate. This means that the drug is able to fish out its 
own targets directly from the biological sample of interest.  
Chemical proteomics approaches include several different experimental 
procedures, however three of them have emerged as most popular: (i) fishing 
for partners (or pull down), which employs a ligand immobilized onto a solid 
support, (ii) global proteomics (quantitative proteomics), in which isobaric 
tags are used to asses changing in protein concentration upon drug treatment, 
and (iii) ABPP, activity-based protein profiling, which uses active site-directed 
probes to record variations in the activity of enzymes in a whole proteome 
(figure 1). 
Since the first approach (i) is the main method used in the development of the 
research projects concerning this thesis, I will focus on it giving some 
examples which clearly show the success of the technique in target discovery 
applications. 
Rix and co-workers, for instance, applied chemical proteomics to the analysis 
of imatinib, nilotinib and dasatinib, three BCR-ABL inhibitors
[4]
. The 
approach successfully led to the identification of the 30 Tyr and Ser/Thr 
kinases which bound to dasatinib, and the receptor tyrosine kinase DDR1 as 
partner of nilotinib. Finally, the oxidoreductase NQO2,  the first non- kinase 
target of these drugs, has been found to bind and inhibit  imatinib and nilotinib 






Fig. 1 Experimental workflows of three different approach in chemical proteomics. (A) 
“fishing for partners”, the compound under investigation is anchored on a solid support. The 
immobilized compound is then incubated with a protein sample to fish its specific partners 
sequentially identify by LC-MSMS. (B) Global proteomic approach. Cell cultures (control and 
drug treatment) are lysed, the obtained proteins digested and peptides analyzed by liquid 
chromatography coupled to tandem mass spectrometry. The quantification is achieved through 
stable isotope labeling. (C) Affinity-based protein profiling (ABPP) involves the incubation of 
the cell extract with a probe able to bind only a subset of all proteins. The tagged protein are 
then recover using affinity chromatography before digestion and LC-MSMS analysis. 
 
Later, pyrido [2,3-d] pyrimidine kinase inhibitors have been used as bait to 
fish out their specific targets from a cell lysate. With this approach, Wissing 
and co-workers identified more than 30 human protein kinases affected by this 
class of compounds
[5]
. The profile of  these inhibitors has been clarified, 
revealing their selectivity for protein kinases possessing a conserved small 








. Again, a chemical proteomic based approach applied to flavopiridol, 
a CDK inhibitors revealed its ability to bind two additional targets, such as 
aldehyde dehydrogenase and glycogen phosphorylase
[6, 7]
.  
Based on these example, it is clear that chemical proteomics could have a deep 
impact on the characterization of small molecule biological targets.    
 
 
1.3.1 Fishing for partners: Outline 
 
The first step in chemical proteomics based experiments consists in enriching 
the small molecule interactome through a pull down affinity assay. The pull 
down assay is based on the development of non covalent and specific 
interactions occurring between the small molecule and its potential binders, 




In more details, the compound of interest (with known or unknown biological 
activity) has to be anchored to a solid support through a spacer arm. This 
matrix is then treated with an opportune lysate, from cells or tissue, to promote 
the interaction between the bait (the anchored compound) and its specific 
protein binders. After several washing steps, useful to reduce the amount of 
non-specific binding proteins, the captured proteins are eluted and subjected to 
either 1D or 2D SDS PAGE, or gel free chromatography.  
The peptide mixtures obtained after trypsin digestion are then submitted to MS 
analysis (usually nano-LC-MSMS) and database search for the final protein 
identification.  
More in general, the procedure should be divided into three main steps: (i) 
drug on-beads immobilization, (ii) affinity purification of the interacting 
proteins and (iii) mass spectrometry identification of the specifically bound 






Fig. 2. The three main steps of fishing for partner approach are depicted. (A) drug on beads 
immobilization, (B)  affinity purification of the interacting protein by the beads bearing drug, 
(C) Mass spectrometry identification of the peptides originating from specifically bound 
proteins. 
 
1.3.2 “Drug on-beads” immobilization 
 
The drug on-beads immobilization is usually achieved through a set of pre-
activated support such as sepharose or agarose. Several activated, able to 
promote the linkage of specific reactive groups, such as sulfhydryl, amino, 
hydroxyl, carboxyl or aldehyde resins, are commercially available. One of the 
main drawbacks of this technique is that only molecules containing one or 
more reactive sites can be attached to a such solid support.  
Otherwise, if synthetic modifications are needed before immobilization, in 
vitro or cell-based assays are required to confirm the activity to be  
maintained. To avoid or reduce steric interferences between the targets and the 
ligand-bearing matrix, the solid support is usually modified with an opportune 
spacer arm. The spacer arm provides an suitable distance between the beads 






bait and the interacting proteins. Different possible linkers have been 





(ethyleneglycol diglycidylether) or an aminocaproylaminopentyloxy, 





Fig. 3. Matrix bearing three different reactive group. (A) 1,1´-carbonyl diimidazole, (B) 
azalactone and  (C) amino spacer group. 
 
One of the most used is the PEG spacer since it increases the hydrophilicity of 
the resin reducing the percentage of non-specific binding proteins, while 
leaving the amount of the specific binders unaffected
[11]
. On the contrary, a 
hydrophobic spacer increases dramatically non-specific binding, making much 
more difficult the following target identification. As a matter of fact, the 
amount of non specific binding proteins could affect the purification efficiency 
because they co-elute with the main targets.  
Another important factor to take into account is the amount of the immobilized 
drug used to fish out the interacting proteins. Indeed, an overloading of the 
drug onto the beads can disturb the interaction between the bait and the 






Fig. 4.  Effect of choice and positioning of the chemical linker. (A) Short spacer linking the 
matrix and the drug increase the steric hindrance and prevents the drug/target interaction. (B) 
A spacer too hydrophobic generates unspecific interaction increasing the amount of non 
specific binding and also preventing targets binding. (C) An optimal chemical spacer with 
mild hydrophobicity grade and with the right length avoids steric hindrance and increases 
targets binding. 
 
On the other hand, a very low immobilization level leaves a  high percentage 
of matrix surface for non specific binding. In general, as reported by Guiffant 
and co workers
[12]
, 3 μmol of drug/mL resin is an optimal concentration to 
minimize the non-specific binding and to increase the specific interactions. 
Therefore, the optimization of “on-beads” drug immobilization is the key step 
of a successful experiment.    
 
 
1.3.3 Affinity purification of the interacting proteins 
 
Actually, affinity chromatography is one of most powerful technique for the 
enrichment of specific binders in a chemical proteomics experiment. 
The small molecule anchored to the solid support is added to an opportune 
protein extract, coming from a cell culture, tissue or serum, to promote ligand-
protein interaction. After the treatment, the bait-bearing matrix is repeatedly 
washed to reduce the amount of the non-specific binding proteins and finally 






The eluted proteins are  sequentially separated by gel electrophoresis, in situ or 
in solution digested with trypsin, and finally analyzed and identified by 
HPLC-MSMS and data base search. 
The identified proteins could be usually divided into several classes: (i) 
proteins exclusively interacted with the linker or the beads, (ii) proteins  highly 
abundant with low affinity for the bait, and  (iii) proteins with high affinity for 
the bait. Several approaches to distinguish specific from non-specific binding 
partners could  be employed. One of the main strategy is to perform a parallel 
experiment using the matrix with only the spacer or an inactive structural 
analog of the drug, as control. Comparison between the protein lists of the 




In another approach an aqueous solution of the free ligand is added at the end 
of the experiment to the beads suspension, enabling the release of the specific 
partners from the beads. This method, often, suffers of the slow dissociation 




Furthermore, if the free ligand is added to the protein mixture before the 
affinity step, it will interact with its partners in solution reducing their binding 
to the beads (bearing the ligand itself)
[14, 15]
. Nevertheless, the use of both 
methods could be limited by the low solubility of the ligand in aqueous 
solution, which does not contain any organic solvent but high concentration of 
several salts and reagents to stabilize protein and to mime physiological 
condition. Dadvar and co-workers successfully applied this approach to the 
discovery of the interactome of the PDE5 inhibitor, PF-3717842
[15]
. By 
applying this method, they were able to enrich for PDE5 and a few other 
PDEs. Moreover, phosphatidylethanolamine-binding protein 2, a protein 
involved in various important signal transduction pathways, has been 




proteomic is a valid technique to discover the interactome of small molecule 
inhibitors. 
 In 2006 Yamamoto and co-workers
[14]
 described an alternative method to 
distinguish non-specific and specific bound protein based on a serial affinity 




Fig. 5. A schematic comparison of serial affinity chromatography is depicted. In serial affinity 
chromatography, specific binding protein is usually captured by the first resin (X1) due to its 
high affinity for the ligand. This causes a large decrease in the amount of protein in the 





The matrix bearing an active compound was incubated with a protein mixture. 
After the removal of the first beads fraction, the same amount of freshly 
prepared beads is added to the same lysate.  
In this case, both resins should capture almost the same amount of background 
proteins, while the specific targets preferentially bind the resin in the first 






Thus, a negative control is  not needed even if the method condition can be 
employed only if the bait-compound shown an high affinity for a specific 
target. As reported in literature, this approach was successfully applied to three 
drugs namely FK506, benzenesulfonamide, and metotrexate. All three 
compounds, immobilized onto a solid support, were subjected to serial affinity 
chromatography revealing their ability to bind selectively FKBP12, carbonic 





1.3.4 Mass spectrometry identification 
 
The key step in proteomics is the identification of the proteins. Actually, two 
complementary approaches, the “top down”
[16, 17]
 and “bottom up”
 [17, 18]
 ,  
have been developed. The top-down proteomics has been introduced several 
years ago and is based on the fragmentation of the intact protein by tandem 
mass spectrometry. The fragments are then analyzed giving a direct 
information on the protein identity. This method is not well established 
because requires ultra-high resolution instruments and bioinformatics 
supports, not yet well implemented. The bottom up approach is actually the 
most popular method in terms of protein identification. It is based on a 
previous enzymatic digestion of the proteins and the tandem mass 
spectrometric analysis of the complex peptide mixtures. The most important 
aspect and probably the main drawback of the bottom up proteomics is  the 
handling and processing of a large amount of data
[18]
.  
The usual proteolytic enzyme in bottom up proteomics is trypsin, a protease 
that cleaves peptides at C-terminus of arginine and lysine residues (figure 6). 
The peptides originated by proteolytic cleavage have a size less than 3 kDa 
and a free amino group at C-terminus, and give rise to doubly and triply 






Fig. 6. Schematic representation of bottom-up and top-down proteomics. In bottom-up 
approach protein identification is achieved through the comparison of the fragmented peptides 
with predicted tryptic fragments deposited in a public database. In contrast, top-down methods 
measure fragments originating by intact proteins. In bottom up, one of the method is based on 
the gel electrophoresis whereas the second method uses two-dimensional liquid 
chromatography (gel free approach) coupled  to mass spectrometry. 
 
The mass spectra of these peptides, especially after CID fragmentation, can be 
easily interpreted due to their y and b fragment types. A combination of 
different proteolytic enzymes, such as Lyc-C and Lys-N, and also the 






protein identification level. The accurate measurement of the peptides masses  
could be compared with “in silico” proteolytic fragments reported in public 
databases. This method, called peptide mass fingerprint (PMF)
[19]
 is mostly 
used with simple peptide mixtures, for example after digestion of a single 
protein spot from 2D electrophoresis. The peptides are extracted from the gel 
and then submitted to MALDI-ToF analysis. Their mass values are then used 
to reveal the identity of the protein by searching in a database.  
With more complex protein mixtures PMF is ineffective, and more 
information about the amino acid sequence and the exact mass of the precursor 
peptides are needed before database search
[20]
. Thus, the peptide mixture is 
subjected to liquid chromatography coupled tandem MS analysis, and the raw 
data are processed to give a peak list submitted to a protein search engine.  
A number of MS/MS web database exist today
[21, 22]
 but, probably, the most 
popular one is Mascot
[23]
, which identifies peptides using a probability based 
algorithm. This web program compares the experimental MS
2
 spectra versus 
theoretical fragment spectra generated “in silico”. The search is user 
dependent, indeed all the parameters like peptide tolerance, proteolytic 
enzyme, miss cleavage and variable modifications have to be defined.  
The search engine collects the identified peptides giving a list of proteins, 
clustered by score, as output. 
 
 
1.3.5 Biological assays to test the identified target 
 
Chemical proteomics experiments are indicative of specific interactions, 
driven by affinity, established between a small bioactive compound and a 
cellular component. The biological relevance of such interactions in terms of 
enzyme inhibition or activation ability is an issue to be determined later on  




results. If the identified protein is an enzyme, an in vitro assay is useful to 
assess the ability of the ligand to modulate its activity. However, the main 
purpose is to provide evidence that the physical association between the ligand 
and the target could affect some biological processes in a living system. This 
goal can be achieved by measuring enzymatic activity, cell proliferation and 
apoptosis at a cellular level. In the case of a protein without enzymatic 
activity, one of the more convincing way to validate proteomics data is to 
generate quantitative interaction parameters, by measuring protein-ligand 
affinity with technique like surface plasmon resonance (SPR) or isothermic 
titration calorimetry (ITC). Nevertheless, the success of both approaches 
depends on availability of the recombinant and purified protein of interest.   
Eventually, it could be very interesting to carried out STD-NMR or co-
crystallization
[24]
 experiments to gain information about the protein-ligand 
interaction mode.  
 
 
1.4.1 Global proteomics 
 
The aim of global proteomics approaches is the evaluation of the whole 
cellular response to drug treatment. Cell cultures or primary cell lines are 
treated with a putative bioactive molecule and the changing in the protein 
expression level are then evaluated in a global and unbiased fashion
[25, 26]
.   
This kind of analysis is usually performed without target enrichment, thus the 
changes observed are often limited to the most abundant proteins. Sometimes 
the analysis is more complicated by the fact that the proteins differentially 
expressed could be unrelated to the pathway modulated by the drug, but often 
represent only highly abundant proteins. 
Moreover, due to the multi-target interaction profile of the drug, several 






proteomic analysis. Global proteomics coupled with target enrichment 
(targeted quantitative chemical proteomics), allows in the analysis of a specific 
intracellular pathway and the measurement of low abundant protein amounts, 
often missed in large-scale studies.  
 
 
1.4.2 An overview of global proteomics approaches   
 
The analysis of the biological processes or protein expression levels occurring 
upon a drug treatment can be done using qualitative or quantitative based 
approaches. The  qualitative approach is only able to assess the presence or 
absence of a specific protein failing in profiling dynamics of protein 
expression. In this cases a quantitative approach is required.  
In the last years, plethora of techniques have been proposed with the aim of 
“absolutely” quantifying differences between two (or more) physiological 
states of a cell system
[27-29]
.Essentially, the global chemical proteomics 
approaches can be divided into two main classes: (i) label-based chemical 





 or dimethyl labeling
[33]
), and (ii) label-free 
based approaches, in which protein abundance is extimated by peptide counts. 
In the next paragraph the label-based approach will be deeply discussed as part 
of this thesis, while only a small section will be dedicated to the label-free 
techniques.     
 
 
1.4.3 Label-based global proteomics 
 
The most used method to quantify different protein levels in different samples 
is the application of the differential isotopic labeling
[27]






Fig. 7. Schematic representation of metabolic and chemical labeling. (A)Metabolic labeling 
(SILAC). Cells are grown  using a media containing respectively SILAC light  and SILAC 
heavy aminoacids; after 100% label incorporation, heavy-labeled cells are treated with the 
compound under investigation for 24 hours. Cells from each sample are lysed, the obtained 
protein mixed and analyzed by LC-MSMS after protelytic digestion. (B) Chemical labeling. 
Cells subjected tosolvent  and drug  treatment  are separately lysed to give a protein sample, 
then digeste using a proteolytic anzyme. The obtained peptides are labelled by iTRAQ or 
dimethyl labelling, mixed and analyzed by LC-MSMS. 
 
Nowadays, stable isotope labeling can be performed at protein and peptide 
levels. In both cases, two cell samples (one of them treated with a drug) are 
differentially exposed to different isotopes. This method allows the analysis of 
two (or more) biological samples in a single analytical experiment, and the 
quantification of the proteins simply by comparing their relative peptide ions 
abundance
[28]






samples make use of metabolic or chemical labeling (figure 7). The stable 
isotope labeling by amino acids in cell culture (SILAC) is a metabolic labeling 
which employs in vivo incorporation of stable isotopes (auxotrophic amino 
acids)
[30]
.The amino acids are supplied in either their natural or in a stable 
isotope form to two cell medium to facilitate their incorporation in the protein 
sequence. One of the cell culture is then subjected to drug treatment and both 
are finally lysed to give two proteins mixture. The differentially labeled 
samples are mixed before protease digestion (usually with trypsin) and then 
subjected to MS analysis and quantitation.  
In another experiment, an isotope tag can be chemically attached onto a 
specific aminoacid at either protein (ICAT)
[31]
 or peptide (iTRAQ)
[32]
 level. 
The quantitation through iTRAQ labeling is based onto the reaction of the free 
amino group of a peptide with N-hydroxysuccinimide esters containing either 
light or heavy  isotopes. Nevertheless, the cost of the iTRAQ reagent and the 
request for a mass spectrometer able of measuring MS/MS fragments at very 
low m/z  have limited the use of this technique.  
An useful technique for labeling at peptide level is the so-called stable isotope 
dimethyl labeling
[33, 34]
. It is virtually applicable to any kind of samples and it 
is less expensive if compared to the other labeling methodologies, and will be 
discuss more in detail in the next paragraph. 
 
 
1.4.4 Stable isotope dimethyl labeling 
 
This method is based onto the condensation of a primary amine (e.g. the free 
amino terminal group of a peptide) with an aldehyde (or ketone) in presence of 
reducing agent
[33]
. Therefore, the peptides are converted in a mixture of N,N-
dimethylamino peptides by treating the sample with formaldehyde and 




epsilon amino group of a peptide side chain giving a Schiff base, then reduced 
to a secondary amine by  cyanoborohydride. An extra reductive alkylation 
occurs immediately after the formation of the secondary amine, giving a 
tertiary amine. By combining different isotope of formaldehyde, a minimum 
of 4 Da difference between two samples could be gained
[35]
. In more details, 
each  peptide could be labeled at the N-termini or at -amino group of lysine 
residues with light (d0) or heavy (d2) formaldehyde originating an increase in 
mass of 28 Da and 32 Da respectively.  
A third label employs the treatment of peptides mixture with 
13
C-labeled (d2)-
formaldehyde and cyanoborodeuteride leading to a mass increase of 36 Da
[34, 
35]




Fig. 8. (A)Triplex stable isotope dimethyl labeling, (B) Mass spectrum of the triplet of the 
labeled isotopomers of the same peptide (the light, intermediate and heavy labeled peptides 
are indicated in green, red orange, respectively). 
 
In a mass spectrometer, the chemical peptide labeled with heavy reagents will 
lead to a mass shift when compared with the light labeled peptide. Therefore, 
the intensity of the peaks in the mass spectrometer is directly connected with 
the relative abundance of the peptides (and of the proteins for inference) in the 






way to analyze three different samples, allowing the quantification of their 
protein expression levels in a single LC-MS run
[36]
. Compared with other 
labeling technique, stable isotope dimethyl labeling can be used with any kind 
of biological samples. Moreover, the labeling reaction is quick, the reagents 
are relatively stable and cheep and it is a high throughput method
[37]
. 
Finally, this tagging approach could be performed also on intact proteins, even 
if the main drawback is the choice of the protease, since trypsin and Lys-C are 
not able to cleave modified lysine residues. 
 
 
1.4.5 Protein identification and quantitation   
 
An important point in performing a correct global proteomics experiment is 
strictly connected with the mass spectrometer performances. As already 
discussed, the heavy and light labeled peptides  are mixed and analyzed by 
mass spectrometry in a single analysis.  
The correct assessment of the mass differences between the light and heavy 
peptides requires a high-resolution mass spectrometer, with Time-of-flight, 
Fourier Transform Orbitrap or Fourier Transform Ion Cyclotron Resonance, 
analyzers, capable of determining peptide precursor charge states and fully 
resolving all ions. These instruments can measure peptide masses and induce 
fragmentation (tandem MS) for determination of their amino acid sequence at 
high resolution.  The protein identification is given by matching the MS/MS 





. These databases are accessible on the Web 
and use different algorithm to score identified proteins through the 
identification of peptide bearing different kind of labeling. After protein 
identification, quantification could be achieved by comparing the peak areas of 




even if software packages, like Mascot Distiller or open source software such 
as MSQuant
[39]
 (http://msquant.sourceforge.net/), are preferred.  
 
 
1.4.6 Label free based approaches 
 
Recently, it has been observed that the number of MS/MS counted during a 
LC-MSMS run is connected to the protein abundance. Thus, the proteins with 




Based on this evidence, label-free based approaches have been developed to 
estimate the protein abundance between two different biological samples
[41]
. In 
this approach, usually named “spectral counting”, samples are analyzed and 
processed separately and the identified proteins are compared in term of 
number of assigned spectra per protein.  
Despite in literature this method is considered as accurate, it fails when only 





1.5 ABPP: activity based protein profiling 
 
ABPP is a functional proteomics technology which employs chemical probes 
specifically designed to react with one class of enzyme
[43]
. An ABPP probe 
consists of two elements: a reactive group containing an  electrophilic site, 
designed to react with a nucleophilic residue in the active site of an enzyme, 
and a tag which is the reporter, like a fluorophore or biotin group
[44, 45]
. 
These radioactive groups (fluorophores) or even affinity tags (biotin), can be 
used as reporters to detect their targets by activity-based probes
[13]
. The 






will interact with its targets reducing the ability of the probe to reveal 
(fluorofore) or enrich (biotin) the enzyme itself 
[46]




Fig. 9. ABPP based approach (A) Structure of a probe, and (B) Reaction between probe and 
target enzyme. The fluorescence tag allow the enzyme detection. 
 
The major advantage of ABPP is the ability to directly monitor the availability 
of the enzyme active site. The combination of tandem mass spectrometry with 
ABPP enables the identification of hundreds of active enzymes from a single 
sample and it is mainly useful for profiling inhibitor selectivity against  
hundreds of targets simultaneously. 
 
 
1.6 Scope and outline of this thesis  
 
Several of the drugs commercially available today are natural products 
obtained from plants, from marine sponges and microorganisms
[47]
. Indeed, 
nowadays natural products isolated from marine sources are emerging as 
potential drug for a plethora of diseases
[48, 49]




source of marine natural products, since they have developed an ability to 
produce secondary metabolites as a defense mechanism against their 
predators
[48]
, and these compounds may have relvant bioactivites  and 





 and Perthamides 
(PRT)
[52]
 are examples of bioactive marine metabolites with a relevant effect 
in experimental models of acute or chronic inflammation. 
PM and BLQ exert their pharmacological activities through the phospholipase 
A2
[51, 53, 54]
 inhibition, as well as through the control of nuclear factor-kB 
activation and NO syntase
[50, 55-57]
, while the exact mechanism of action of 
PRT, in acute inflammation, is currently under investigation. 
The pharmacological properties showed by these metabolites seem not be 
related to a single enzyme inhibition, for instance sPLA2 or NF-kB.  
Thus, a fully investigation of their interactome has been considered of a broad 
interest to better understand their mechanism of action and potential multiple 
effects.  
As reported previously, the only way to better understand the drug’s poly-
pharmacological activities and toxicity is a comprehensive characterization of 
the drug interaction with cellular components. 
Therefore, the primary purpose of the projects involved in my PhD thesis has 
been a comprehensive characterization of the interactome profile of the above 
mentioned marine metabolites. I have applied a chemical proteomics-based 
approach to discovery the main cellular partners of each compound validating 
all the results through biological assays.   
In chapter 2 the determination of the interactome of Petrosaspongiolide M is 
described. This metabolite has been anchored to a solid support to fish out its 
proteins partners from a complex cell lysate. The 20S proteasome has been 
identified as main partner. In vitro and in cell fluorescence assays have 






system. The results have clarified Petrosaspongiolide M effects at NF-KB 
level. 
In chapter 3 the same approach has been applied to the analysis of the 
interactome of the marine metabolite Bolinaquinone. In this case clathrin, an 
“unexpected” target not directly connected with the BLQ anti-inflammatory 
properties, was identified. The BLQ ability to modulate clathrin mediated 
endocytosis has been assessed trough cytofluorimetric and microscopy 
analysis, suggesting a new application of BLQ as biothecnological tool in the 
modulation of trafficking pathways. 
In chapter 4  Perthamide C, a novel cyclopeptide showing anti-inflammatory 
properties, has been analyzed by chemical proteomics and Endoplasmin, an 
endoplasmic reticulum heat shock protein, has been identified as its main 
partner. 
Finally, to expand my knowledge in chemical proteomics-based approaches, I 
have applied quantitative chemical proteomics to discover the effect of 
collagen on platelet activation. Since cAMP and cGMP play a key role in 
platelet activation, I have described, in chapter 5, the combination of 
quantitative chemical proteomics approach with the specific enrichment of 
cAMP/cGMP signaling nodes, with the aim to understand how PKA but also 
cGMP-dependent protein kinases (PKG) spatially reorganizes in activated 
human platelets. 
 





































Chemical Proteomics Discloses Petrosapongiolide M, an 
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2.1 Gone Fishing: Petrosaspongiolide M 
  
Marine sesterterpenes containing -hydroxybutenolide moiety have been 
studied for their potent anti-inflammatory activity since the discovery in 1980 
of manoalide, which is considered the reference compound in this research 
field 
[58]
. Since then, a number of  -hydroxybutenolide-containing metabolites 
have been isolated, for instance luffariellolides, luffariellins, luffolide, 




Among the -hydroxybutenolide-containing compounds, Petrosaspongiolide 
M (PM, figure 10) has been subjected to a comprehensive in vitro
[61]
 and in 
vivo 
[62]
 pharmacological investigation. In more detail, PM shows an IC50 of 
0.8 M toward human synovial PLA2
[63, 64]
 and is able to reduce the levels of 






Fig. 10. Chemical Structure of Petrosaspongiolide M. 
 
In addition, an in-depth pharmacological investigation has revealed that PM 
also interferes with NF-B pathway, strongly decreasing NF-kB–DNA 
binding
[62]
. Nonetheless, whether PM exerts its pharmacological effects 
through binding and/or modifying specific proteins remained unknown
[62]
. 





Since the NF-kB pathway plays a crucial role in the development of the 
inflammation response, it would be desirable to identify the primary PM 
partners, suitable as potential therapeutic targets. To reach this goal, a 
chemical proteomic strategy, using affinity chromatography coupled with 
mass spectrometry, has been applied to macrophage cell proteomes
[66-68]
. 
From an experimental point of view, our work can be divided into the 
following steps: (i) chemical immobilization of PM on a solid support; (ii) 
incubation of PM-modified beads with cell lysates; (iii) MS identification of 
PM interactors; (iv) determination of physical interaction between PM and the 




2.2 Chemical immobilization of PM on a solid support 
 
The chemical immobilization of a small molecule ligand is usually achieved 
through suitable functional group. PM was anchored onto a solid support, 
taking advantage of its electrophilic functional group, the masked aldehyde on 
the -hydroxybutenolide ring. 
We selected a Reacti-Gel (6X) matrix  beads consisting of agarose activated 
by 1-1’-carbonyl-di-imidazole functions. In addition,  to the  introduction of a 
spacer between PM and the Reacti-Gel (6X) beads was necessary to avoid 
possible steric hindrance between the macromolecular target(s) and the 
immobilized ligand. A set of possible linkers, such as 1,5-di-amino-pentane 
(DAP), 1,12-di-amino-dodecane (DAD), 4,7,10-Trioxa-1,13-tridecanediamine 
(PEG), different in terms of length and hydrophilic properties, have been 
tested to minimize non-specific protein binding and maximize purification 
efficiency. The linkers were bound to the matrix via nucleophilic attack of 
their terminal amino group onto the carbonyl function of Reacti-Gel (figure 




11). The linker-bearings matrix were then subjected to Kaiser test, prior PM 




Fig. 11. Reaction scheme of the beads with 1,12-di-amino-dodecane, 5-di-amino-pentane, and 
4,7,10-Trioxa-1,13-tridecanediamine. 
 
Then, PM was treated with the amine-modified beads to obtain PM-DAP-
beads, PM-DAD-beads and PM-PEG-beads, respectively. As reported in 
figure 12, the imine bond occurring between the masked aldehyde at C-25 of 
PM γ-hydroxybutenolide ring and the free amino group of the linker was 
selectively reduced by NaBH4.  
The experimental conditions (buffer, pH, reaction time and temperature) were 




The yield was calculated by the integration of RP-HPLC peaks relative to the 
PM concentration before and after the treatment with the different beads. The 
coupling process was completed by blocking the remaining active groups with 
acetic anhydride.  
As a control, a portion of the activated Reacti-Gel (6X) support was mixed 
with the three different diamines and the free amino groups were capped with 
acetic anhydride. 







Fig. 12. Preparation of PM-modified beads. 
 
 
2.3 Affinity purification of PM interacting proteins 
 
2.3.1 Cell lysate  
 
Since PM has been investigated for its anti-inflammatory properties, we 
selected the same model system for our analysis
[62]
.  
Thus, THP1 monocytic cells were differentiated in macrophages by treating 
them with phorbol ester (PMA) upon LPS treatment to induce an 




inflammatory response. Finally, the cells were scraped out and lysed to obtaine 
the whole cell lysate used for the following affinity purification experiments. 
 
 
2.3.2 Affinity purification and mass spectrometry analysis of PM partners  
 
Before starting PM target purification, we evaluated the effects of the above 
mentioned spacers on the non-specific protein binding level. Indeed, non-
specific binding of cellular proteins to affinity matrices is a significant 
limitation to this approach, and the reduction of such binding is an important 
outcome. Thus, we compared the gel electrophoretic profile of PM-DAP-
beads, PM-DAD-beads and PM-PEG-beads after the incubation with the THP-
1 cell lysate (figure 13).  
The resin bearing hydrophilic PEG spacers showed a moderate degree of 
nonspecific binding proteins, when compared with the other samples, and was 




Fig. 13. Electrophoretic profile of PM beads bearing three different spacer arm. The amount of 
total proteins eluted is reduced by beads modification with hydrophilic PEG spacers. 





The crude cell extracts of LPS induced THP-1 were treated with the PM-PEG-
beads to promote the interaction between PM and its potential partners in the 
cell lysate. Cell extracts were also incubated with a PM free matrix, as a 
control experiment, to distinguish between specifically bound components and 
background contaminants. 
After extensive washings, the PM interacting proteins were released from the 
resin by elution with SDS-gel loading buffer. The protein mixtures were then 
resolved by SDS-PAGE
[70, 71]
, and the gel lanes, of the PM beads and control 
experiments were cut in 13 pieces, digested with trypsin, and analyzed by 





Fig. 14. Representation of the chemical proteomic experiments applied to the discovery of PM 
targets. The proteins retained in the PM-affinity step were eluted from the support, subjected 
to SDS PAGE separation, digested in situ, and identified by mass spectrometry. 




Doubly and triply charged peptide species obtained in the conventional MS 
spectrum were fragmented, and all the MS/MS spectra converted into a peak 




2.3.3 PM interactors 
 
The outcome of the Mascot database search revealed the whole interactome of 
PM. A list of identified proteins, from both gel lanes (control and matrix 
bearing PM), was obtained and compared to establish which proteins were 
specifically captured by PM. As reported in the Venn diagram (figure 15), 325 
proteins were observed in both experiments while 29 only  were exclusively 




Fig. 15. Venn diagram showing the number of proteins identified in either or both binding 
experiments. 
 
These proteins were considered as potential PM interactors (table 1). Several 
of the proteins reported in Table 1 are highly expressed in THP-1 cells
[72]
, and 
their presence, typical in this kind of analysis, is due mostly to their abundance 
rather than to a real affinity to the ligands
[67, 72]
.  







Tab. 1. Proteins identified as PM interactors (clustered by function). 
 




We were particularly intrigued by the presence of several components of the 
proteasome enzymatic machinery, since the ubiquitin–proteasome system 
(UPS) is responsible for the degradation of most intracellular proteins, 
including those that control cell cycle progression, apoptosis, signal 
transduction, and the NF-kB transcriptional pathway
[73-75]
. As these findings 
were strictly connected with the previously reported pharmacological 
evidence
[62]
, we performed an in-depth investigation on the biological role of 
PM in the interaction with the proteasome machinery, through in vitro and in 
living cells assays. 
 
 
2.4 Characterization of physical interactions between PM and 20S 
proteasome 
 
Surface plasmon resonance (SPR) Biacore technology was employed to 
quantify the interactions of PM with the human recombinant 20S 
proteasome
[76]
. SPR is an optical technique, based on the evanescent wave 
phenomenon, able to measure changes in refractive index onto a sensor 
surface, and it is suitable for characterizing macromolecular interactions
[77-79]
. 
The binding between a compound in solution and its ligand immobilized on 
the sensor surface results in a change of the refractive index, that could be 
monitored in real time allowing the measurement of association and 
dissociation rates. 
We attempted to measure the kinetic dissociation constants between PM and 
the 20S proteasome by anchoring PM onto the chip surface through a di-amine 
PEG spacer (PEG). More in details, the PEG spacer, containing an NH2 group 
coupled with a trityl group (trt), was bound onto the chip surface pre-activated 
by EDC/NHS. The trt group was removed by injection of  1% TFA solution, 
to give a free amine group able to react with the PM aldehyde function. 





Indeed, PM was injected on the chip surface, and the Schiff base formed 
between the masked aldehyde on PM and the free amino groups on the chip, 
was then reduced by NaBH4 (figure 16). The PM immobilization was assessed 
by measuring an increase of response units (RU) of 800 on the SPR trace. 
As additional test to prove the PM immobilization, a sample of bee venom 
PLA2, a well known PM interactor
[80]
, was injected onto the chip surface and a 
strong binding (KD in the low nano molar range) was calculated that gave us 
the confidence of a successful ligand immobilization.   
Then, different concentrations of 20S Proteasome (1 to 100 nM), in presence 
or absence of its activator PA28
[81]





Fig. 16. PM on chip immobilization. (A) Sensor surface activated with EDC/NHS mixture has 
been modified with trt-NH-PEG-NH2; (B) To give a free amine a solution containing 1% TFA 
has been injected onto the chip surface; (C) The free amine on chip surface reacts with PM 
aldehyde and was reduced by NaBH4. 




In figure 17 are shown the sensograms detected after the binding of 20S-PA28 
complex to PM, at two different concentrations. The increase of response units 
(RU) in the association phase and the slope of the dissociation phase of the 
complex are clearly dependent on the analyte concentration. 
Association and dissociation rate constants were determined, and equilibrium 
binding constants (KD) of 8 (±3.1), and 0.7 (±1.1) nM were calculated for 20S 
and 20S-PA28 complex respectively, demonstrating the strong interaction 




Fig. 17. Sensograms obtained from the binding of PM to 20S-PA28 in presence of CaCl2 at 
two different concentrations. 
 
 
2.5 20S proteasome inhibition by PM: in vitro assay 
 
Proteasome is a large protein complex inside all eukaryotes and archaea, as 
well as in some bacteria
[82]
. The main proteasome function is to induce the 
degradation of unneeded or damaged proteins by proteolysis. All proteins 
tagged with poly-ubiquitin chains are recognized and hydrolized by the 
proteasome
[83, 84]
, yielding short peptides (seven to eight amino acids long), 
following converted into amino acids. Proteasome is a large barrel-like 
complex consisting of a “core” of four rings around a central hole. Each ring is 
composed of seven different proteins; two rings are made of seven β subunits 





and the other two contain seven α subunit each.
[85]
 Moreover, β subunits ring 
contains six protease active sites located in the β1, β3 and β5 subunits. The 
roles of the α rings are to maintain a "gate" through which proteins can enter 
the barrel and bind a "cap" structures or regulatory particles that recognize 
poly-ubiquitin tags. 
After an initial recognition step, proteins are degraded by three catalytic β 
subunits (β1, β3 and β5). Although they have a common mechanism, they 
have slightly different substrate specificities, which are considered 
chymotrypsin-like (β5), trypsin-like (β1), and peptidyl-glutamyl peptide-
hydrolyzing (PHGH)-like (or caspase-like, β3)
[85]
.  
The activity of PM on the 20S human proteasome (the catalytic subunit of the 
entire 26S proteasome) was tested in vitro by detecting its ability to modulate 
the 20S-mediated proteolysis of fluorogenic peptide substrates, each specific 
for a particular catalytic subunit of the enzyme (see experimental section for 
details)
[86, 87]
. All these peptides are enzymatic substrates containing  7-amino-
4-methylcoumarin (AMC) as fluorophore. In such substrates, the AMC is 
typically linked to the peptide through formation of an amide bond between 




Fig. 18. Principle of AMC-labeled fluorogenic substrates. 
 
Proteolysis of this amide bond gives free AMC, resulting in a large increase in 
fluorescence that can be detected at 460 nm upon excitation at 350 nm. As 




reported in literature, to prime 20S proteasome activity we incubated it with 
Proteasome activator complex (PA28)
[81, 88]
. Then, we treated the activated 
proteasome with different concentrations of PM (0.5–5 M) before the 
addition of a site specific fluorogenic substrate. The proteasome degradation 
occurs and the fluorescence moiety is released in solution, leading to a large 
increase in fluorescence, upon excitation. The comparison of the fluorescence 
emission of the PM-treated enzyme mixture with that of control (DMSO) 
allowed us to demonstrate the PM effect on each proteolytic site. In more 
details, we found that PM directly inhibits the proteasomal activity, in 
particular its caspase- and chymotrypsin-like activities with IC50 of 1.8 (±0.23) 




Fig. 19. In vitro Petrosaspongiolide M inhibition of 20S proteasome. Bars shows PM effect 
(0.5-5 μM) on recombinant 20S-PA28 proteasome complex activities. The caspase and 
chymotrypsin-like activity are inhibited by PM, whereas the trypsin like activity is fully 
activated. The data confirm a direct interaction between PM and proteasome. 
 
As shown in figure 19, PM stimulates the trypsin-like activity of the 
proteasome at the tested concentrations. This is not surprising, since this effect 





has been already reported for several inhibitors of caspase-like site which 
allosterically stimulates the trypsin-like activity
[87]
. Furthermore, it is well 
known that the inactivation of the chymotrypsin-like site is the main event 





2.6 Cellular Inhibition of 26S Proteasome Activity by Petrosaspongiolide 
M 
 
In a following experiment, we have assessed the ability of PM to inhibit 
proteasome functions inside the cell. Since proteasome inhibitors are known to 
be extremely cytotoxic, a MTT cell viability assay was performed to evaluate 
PM cytotoxic effects at the appropriate concentration for proteasome 
inhibition. Indeed, as reported in figure 20, PM did not produce significant 
cytotoxic effects, even at 1 M, after 24 h of incubation.  
 
 
Fig. 20.  PM effect on cell viability. % Cell survival of THP1-LPS induced macrophages at 
different concentration of PM All the experiment were triplicate and normalized to control 
(DMSO). 
 
Then, THP-1 macrophages were incubated with PM in a concentration range 
between 0.1–1 M. After 24 h, PM treated and control (DMSO) cells were 




scraped out and lysed. Proteasome activity inside the cell lysates was 




Fig. 21. Effect of PM inhibition on 26S proteasome in cells. (A) Effect of PM (0.1–1 μM) and MG132 (1 
μM) on 26S proteasome activities in cells. (B) Western blot analysis of polyUP accumulation after 
treatment with PM (0.1–1 μM) and MG132 (1 μM). 
 
The fluorescence emission of PM treated cell lysate was compared with that of 
control (DMSO), as for in vitro experiments, showing a significant inhibition 
by PM of the caspase- and the chymotrypsinlike activity, with IC50 values of 
0.85 (±0.15) M and 0.64 (±0.11) M, respectively. The trypsin-like activity 
resulted to be activated, as already reported for in vitro based assays (figure 





21A). In the same test, the reference compound MG132, a well-known 
proteasome inhibitor
[89]
, was found to be slightly more effective than PM on 
the inhibition of chymotrypsin and caspase activity, and a similar behavior 
was observed for the modulation of the trypsin-like activity (figure 21A). 
Since the specific inhibition of proteasome produces the accumulation of 
polyubiquitinated proteins, we wanted to improve the biological profile of PM 
testing its effect on the accumulation of polyubiquitinated proteins (polyUP) 
by immunoblot analysis. After treatment of THP-1 macrophage cells with PM, 
lysates were analyzed by western blotting using polyubiquitin antibodies
[90]
. 
The immunoblot profile in figure 21B demonstrated a relevant degree of 
polyUP accumulation in the cells treated with PM, increasing in a 
concentration-dependent manner. A major effect was evident in the case of 
MG132 due to its higher potency of action.  
Since the UPS abnormal activation or failure underlies the pathogenesis of 
many human diseases
[75, 84]
 (i.e. cancer, inflammation, cardiovascular diseases, 
neurodegenerative disorders), its modulating agents are considered attractive 
molecules for pharmacological intervention. In particular, two proteasome 
inhibitors have entered clinical trials for the treatment of cancer (Bortezomib) 
and stroke patients (MLN-519)
[91]
, of which the first is already commercially 
available. On this basis, the relevant blocking of the proteasome activity in the 
living cells demonstrated by PM suggests this molecule as a potential new lead 
compound. Detailed investigations on the molecular mechanism of this 






















Chemical Proteomics Reveals Bolinaquinone as a Clathrin- 
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3.1 Fishing out BLQ target 
 
Bolinaquinone (BLQ, figure 22) is a sesquiterpene metabolite isolated from 
the marine sponge Dysidea sp. in 1998 by Ireland and co-workers
[92]
.  
Chemically, BLQ is a terpenoid derivative characterized by a rearranged 






Fig. 22. Bolinaquinone (BLQ) chemical structure. 
 
The field of quinone–protein chemical interactions is quite intriguing, as a 
result of multiple reaction pathways, including nucleophilic additions and 
redox processes. Indeed, quinone/hydroquinone redox species are often 
involved in single-electron transfer (SET) processes, which ultimately elicit 
chemical inactivation of several proteins and enzymes
[93-95]
. 
BLQ was extensively studied as anti-inflammatory compound and its PLA2-
inhibition properties
[96, 97]
 and anti-inflammatory pharmacological profile were 
thoroughly examined, both in vitro and in vivo
[98]
. 
In particular, BLQ is able to reduce the production of mediators in acute and 
chronic inflammation and is a modulator of the oxidative stress parameters in 
2,4,6-trinitrobenzenesulphonicacid (TNBS)-induced colitis in mice
[99]
. 
Moreover, as reported by Busserolles and co-workers, BLQ dramatically 
reduces nitrotyrosine immunodetection and colonic superoxide anion 
production, and furthermore decreases the extension of apoptosis, suggesting 




potential protective actions in intestinal inflammatory diseases
[99]
. Due to its 
interesting anti-inflammatory profile
[98, 99]
, BLQ is a good candidate for a 
target discovery study aimed to the identification of its primary partners, and 
to a better understanding of its mechanism of action. To reach this goal, a 
chemical proteomics-based approach has been employed. From an 
experimental point of view, our approach to determine the BLQ interactome 
can be divided  into three steps: (i) Generation of functional BLQ-modified 
beads, (ii) affinity purification and MS identification of BLQ specific 
interacting partner(s), and (iii) in cell assays to test its biological effect(s).  
 
 
3.2 Generation of functional BLQ-modified beads 
 
The immobilization of a compound on the matrix beads usually requires the 
interposition of  a spacer arm to minimize steric hindrance between the ligand 
and its macromolecular partners in the following step of affinity purification, 
as already reported for PM in chapter 1. The spacer arm can be inserted on the 
particle surface before the immobilization of the compound, even if an 
increase in the non-specific protein adsorption has to be expected, due to 
several unmodified reacting groups of the spacer after the following step of 
immobilization. 
An improvement in term of target binding ability and reduction of non-specific 
binding can be obtained by a prevoious reaction between the spacer and the 
sample compound and the following immobilization on the resin.   
On this basis, BLQ was treated with 4,7,10-trioxa-1,13-tridecanediamine 
(NH2-(PEG)2-NH2) to give a covalent adduct (BLQ-NH-(PEG)2-NH2), 
through a Michael-like addition of the spacer amino group onto the conjugated 
quinone moiety followed by methanol loss (figure 23), as already reported
[96, 
97]
. The reaction was monitored by HPLC-MS, allowing the identification of 









Fig. 23. Reaction scheme of BLQ chemical modification with 7,10-Trioxa-1,13-
tridecanediamine. 
 
Finally, several HPLC runs were carried out to isolate enough amount of BLQ 
modified species. The purified BLQ adduct was then immobilized onto the 
agarose Reacti-Gel beads by a nucleophilic attack of the terminal NH2 group 
onto the activated carbonyl function of the resin, followed by imidazole loss 




Fig. 24. BLQ immobilization onto the Reacti-Gel (6X) support. 
 
The yield of the  immobilization process was evaluated by integration of RP-
HPLC peaks of free BLQ-NH-(PEG)2-NH2 before and after the incubation 
with the beads. Figure 25 shows the peaks of free BLQ-NH-(PEG)2-NH2 in 50 
µl of reaction buffer with Reacti-Gel agarose matrix after 0, 2 and 16 h 
incubation. The high decrease of the peak area revealed the anchorage of the 
BLQ-NH-(PEG)2-NH2 adduct onto the beads with a 60% immobilization 
yield. The experimental conditions such as buffer, pH and temperature (see 




Material and Methods section) were optimized to reach final concentration of 





Fig. 25.  Chromatographic profile of free BLQ-NH-(PEG)2-NH2  after 0, 2 and 16 h incubation 
with Reacti-Gel agarose matrix. 
  
Finally, a control sample was prepared treating a trityl-modified spacer adduct 
with  the Reacti-Gel (6X) resin. Both modified matrix species were then stored 
in acetone at 4°C. 
 
 
3.3 Affinity purification and MS identification of BLQ specific interacting 
partners 
 
3.3.1 Fishing for Partners 
 
The analysis of BLQ-interacting protein(s) started with the treatment of the 
BLQ modified beads with a lysate of THP1 induced macrophages, the same 








The same amount of protein sample, obtained from LPS induced THP-1, was 
incubated with the BLQ modified beads and with a BLQ free matrix sample, 
as control experiment. After incubation, non-specific bound proteins were 
mostly released by an extensive washing of the beads, while the tightly bound 
proteins were eluted with SDS loading buffer and then chromatographed by 
1D-SDS PAGE.  As expected, a clearer electrophoresis profile was obtained if 
compared with that of the PM experiment (see chapter 2), because of the 




Fig. 26. SDS PAGE analysis of the affinity purified proteins. 
 
In an affinity purification analysis, an unbiased way to perform the 
identification of the specific interactors of a given compound requires the 
analysis of the entire gel lanes 
[101]
, as  performed in the case of the PM 
interactome analysis (see chapter 1). However, in this case the comparison of 
the electrophoretic runs (beads-BLQ vs control) displayed a major protein 




enrichment at an apparent molecular weight of 190 kDa (figure 26). On this 
basis, we focused our attention on this gel region that we cutted out and treated 
as reported by Schevchenko et al. 
[102]
 obtaining tryptic peptide mixtures. Even 
though the BLQ enrichment on the gel looked convincing, we wanted to take 
into account the worst case in which a protein smearing from the upper strong 
band inside the gel giving false positive enrichment. For this reason, we 
enlarged the cutted region to the upper bands both in control and BLQ-based 
experiment (Figure 27A). The peptide mixtures generated after trypsin 
digestion were submitted to LC MS/MS analysis. Fragmentation of doubly and 
triply charged peptide species was performed and all MS/MS spectra were 




3.3.2 BLQ interactors identification 
 
The Mascot database search allowed us to identifiy the main BLQ targets. All 
the proteins identified in the gel region showing the most prominent BLQ 
enrichment, were compared in term of spectral counts with that of the control 
ones. As reported in the spectral count table (Figure 27B), the upper strong 
band (in blue) contains different isoforms of myosin with the same extent both 
in the control and BLQ experiments, whereas clathrin is almost exclusively 
contained in the strong band enriched in the BLQ experiment (in red). 
Therefore, the sequence coverage, the Mascot and the peptide scores obtained 
for clathrin were enough to convince us about the confidence of our 
identification (figure 27C). On this basis, clathrin, a key protein involved in 
the receptor mediated endocytosis processes, has been recognized as BLQ 
interactor indicating that this marine metabolite is able to fish out from a cell a 
main intracellular partner with high specificity. Since BLQ is characterized by 




an interesting anti-inflammatory profile
[98]
, this result is somewhat unattended; 
thus we were intrigued by a new potential application of BLQ and decided to 
perform additional experiments to confirm clathrin as main BLQ partners. 
 




Fig. 27. MS identification of BLQ main target. (A) Zoom in the 8% of polyacrylamide gel 
region around 210 kDa. The upper bands (# 1 in blue) from control and BLQ beads were 
separately cut and analyzed as well as the lower bands (# 2 in purple). (B) Identification of 
proteins eluted in the upper (in blue) and lower (in purple) bands from control and BLQ beads. 
Number of assigned spectra for identified protein are reported. The table represents one of 




3.3.3 Serial affinity chromatography as a tool for identifying specific BLQ 
binding protein 
 
In 2006, Yamamoto and co-workers developed a method to distinguish 
specific bound proteins from the unspecific ones. This method employs the 
sequentially treatment of the protein mixture with two affinity resin samples 
bearing the same bioactive ligand. The proteins eluted from each affinity step 
are chromatographed by 1D-SDS PAGE and comparatively analyzed. The 
recovery of the specific binding proteins is significantly higher in the first 
affinity step than in the second one, because of their high affinity for the 
ligand. On the contrary, nonspecific binding proteins are almost equally 
captured during the affinity steps, due to their low affinity for the resins
[103]
. 
On this basis, we applied the serial chromatography approach to our case.  
A THP1 cell lysate was sequentially treated with three batches of affinity 
beads bearing BLQ, and the proteins bound on each resin (corresponding to 
A1, A2 and A3 lanes on the gel in figure  28) were comparatively analyzed by 
1D-SDS PAGE.As expected, the binding of clathrin (the band at around 190 
kDa) is significantly reduced on the second and third affinity step (A2 and A3) 
when compared with the first one (A1), as a sign of a selective capture by 
BLQ. These findings are extremely convincing about the confidence of 
clathrin identification as BLQ main partners. The evidence that clathrin binds 




BLQ selectively can open the way to further investigation on the role of BLQ 
in the modulation of clathrin-mediated processes, in a cell system.  
Thus, we were intrigued by a new potential application of this molecule in 
modulating biological processes, such as clathrin-mediated internalization, and 




Fig. 28. Serial affinity chromatography experiment. THP1 cell lysate was sequentially treated 
with three batch of BLQ-modified resins and proteins eluted from each resin (A1, A2 and A3) 
were resolved using 8% SDS-PAGE. 
 
 
3.4 In vivo BLQ biological effect on Clathrin mediated endocytosis 
 
Endocytosis plays an important role in the selective uptake of proteins, viruses 
and other biologically important macromolecules at the plasma membrane of 
eukaryotic cells. Receptor-mediated endocytosis allows the specific removal 
of cell surface receptors from the plasma membrane and targets them to 
endosomes
[104]
. Clathrin is the main component of the coated vesicles that 




mediate the selective transfer of molecules from the extracellular environment 
within cells. In all cell types, clathrin-coated vesicles are responsible for 
receptor-mediated endocytosis at the plasma membrane and for the receptor-
mediated sorting of lysosomal enzyme. In cells with a regulated secretory 
pathway, clathrin-coated membranes are involved in the formation of 
secretory granules and in the rapid uptake of plasma membrane following 
degranulation. A number of protein-protein and protein-lipid interactions 
underlies the assembly of the clathrin-based endocytic machinery. In addition 
to clathrin, AP-2, and some other accessory cytosolic proteins, including 
synaptojanin I and Eps15, are involved in vescicle formation
[105, 106]
.  
At each site, clathrin associates indirectly with the membrane by binding to an 
adaptor protein (AP), which interacts with the cytoplasmic domains of 
transmembrane receptors. Polymerization of clathrin then catalyze the 
assembly of adaptors associated receptors and their bound ligands into a 
coated vesicles.Since the clathrin mediated endocytosis pathway plays an 
important role in the selective uptake of proteins, viruses and other 
biologically important macromolecules, the modulating agents of clathrin-





Fig. 29. Schematic rapresentation of clathrin-coated vesicles formation. 




On this basis, we decided to verify the biological relevance of BLQ towards 
clathrin-mediated endocytosis.  
More in details, we studied the clathrin dependent internalization of albumin 
by means of a fluorescence assay. Indeed, since albumin is fully internalized 
by a pure clathrin-dependent mechanism
[107]
, we chose this protein to test the 
ability of BLQ to interfere with clathrin dependent internalization. 
Chlorpromazine (CPZ), a well known inhibitor of clathrin-mediated 
endocytosis, was selected as refernce compound. Before starting the 
internalization experiments, an MTT assay was performed to evaluate the 
cytotoxic effect of BLQ at the concentration used in the clathrin experiment. 
The cells, seeded into 96 well plate, were exposed to different concentrations 
of BLQ (0.01 to 100 M) and incubated for 48 h. The mitochondrial-
dependent reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) to formazan was used to evaluate the possible BLQ cytotoxic 
effect. As reported in figure 30, BLQ did not produce significant cytotoxic 




Fig. 30. % cell survival of THP1-LPS induced macrophages at different concentration of BLQ 
after 48 h of incubation. Each value is the mean ± standard deviation of three different 
experiment performed in triplicate. 




Then, we analyzed the ability of THP1 induced macrophages to internalize a 
fluorescent-labeled albumin (488-BSA) in presence and absence of BLQ and  
CPZ
[107, 108]
. In a first step the internalization assay was optimized by 
incubating macrophages cells with two different concentration of 488-BSA 
(10 g/ml, 20 g/ml) and with the solvent (control), and then analyzing the 
cells by flow cytometry. 
As depicted in figure 31, the shift in the maximum fluorescence intensity in 
the two experiments vs control is clearly due to the BSA internalization. Since 
the incubation with 10 and 20 g/ml BSA gave similar results, we decided to 




Fig. 31.  FACS analysis of 488-BSA uptake, at two different concentrations, in THP1 
macrophages. 
 
Once the protocol was optimized, THP1 macrophages were pre-incubated with 
BLQ or CPZ (50 and100 , before the addition of the green 
fluorescent 488-BSA. Figure 32 clearly shows the similar effect of BLQ and 
CPZ on 488-BSA internalization, providing the evidence of BLQ interference 
on the clathrin-mediated endocytosis. 






Fig 32. (A-B) FACS analysis of 488-BSA uptake in THP1 macrophages in presence and 
absence of different concentrations of BLQ and CPZ. Ctr: cells incubated in normal cell 
growth. 
 
The same data, reported as percentage of 488-BSA internalization (figure 33), 
clearly showed that both BLQ and CPZ decrease the uptake of 488-BSA in a 




Fig. 33. Histograms representing the percentage of 488-BSA internalization calculated by the 
median fluorescence intensity values measured by CellQuest Software. The 488-BSA 
internalization at 20 g/ml was set as 100%, the data are representing three different 
experiments ±sd. 




Since 488-BSA is tagged with a fluorescence probe, we decided to evaluate 
BLQ and CPZ modulation of BSA internalization also by miscroscopy 




Fig. 34. Cells microscopy analysis: (A) after incubation with 488-BSA, (A) after 
preincubation with CPZ 100μM and incubation with 20 μg/ml 488-BSA, (C) after 
preincubation with BLQ 100μM and incubation with 20 μg/ml 488- BSA. 
 
All these data clearly demonstrated the ability of BLQ to inhibit the clathrin-
dependent internalization process in a dose-dependent manner (figure 33-34).  
Since only few organic compounds are known to modulate clathrin-dependent 
endocytosis (for instance CPZ and amantadine
[107]
), BLQ could be considered 
as a biotechnological tool with a novel chemical scaffold for the investigation 
of cellular internalization and trafficking pathways. 
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4.1 Chemical Proteomics applied to the discovery of Perthamide C 
interactome 
 
Perthamide C (PRT, Figure 35) is a cyclic peptide isolated from an Australian 






Fig. 35. Chemical structure of Perthamide C (PRT). 
 
Chemically, PRT is a cyclic peptide containing both natural and un-natural 
aminoacids such as O-methylthreonine (ThrOMe), 2-amino-2-butenoic acid 
(dAbu), N-methylglycine (NMeGly), γ-methylproline (γMePro) and β-
hydroxyasparagine (bOHAsn) leading an additional sulfate and amidic group. 
Since marine sponges of the genus Theonella are an excellent source of 
bioactive peptides with interesting biological activities, PRT has been 
subjected to an in vivo investigation to test its anti-proliferative and anti-
inflammatory activities. PRT C did not show anti-proliferative activity on KB 
cell lines up to a dose of 10 mg/mL. However, it is able to significantly reduce 





carrageenan-induced paw oedema both in the early (0–6 h) and in the late 
phases (24–96 h). Moreover, PRT showed a dose dependent anti-inflammatory 
profile, which lead to a 60% reduction of the oedema, in mice, when 
administered at 300 g/Kg. Its anti-inflammatory profile resulted 100 times 














inflammatory profile has opened the way to further investigations on its origin. 
Aiming to a comprehensive characterization of PRT interactome in a cellular 
system, a chemical proteomics based approach has been employed. 
The experimental approach could be divided into the following steps: (i) 
generation of functional PRT-modified beads, (ii) affinity purification and MS 
identification of PRT specific interacting partner(s), and (iii) surface plasmon 
resonance (SPR) experiments  to measure the affinity between PRT and its 
target proteins.   
 
 
4.2 Generation of PRT functional matrix 
 
4.2.1 PRT reaction profile with  4,7,10-trioxa-1,13-tridecanediamine 
 
As mentioned into previous chapters, the immobilization of a small molecule 
on the matrix beads needs a spacer arm to minimize steric hindrance between 
the ligand and its macromolecular partners during the affinity purification 
step. Moreover, in BLQ based experiment (see chapter 3), we have 
demonstrated that the modification of the drug with the spacer before the 
immobilization on the beads strongly reduces the amount of non-specific 
adsorption. On this basis, we decided to modify PRT with 4,7,10-trioxa-1,13-




tridecanediamine (NH2-(PEG)2-NH2) before its immobilization on the matrix.  
The reaction was monitored by HPLC-MS allowing the identification of a 
covalent adduct (Mw: 1226.54 Da) generated through a nucleofilic attack of 





Fig. 36. Reaction scheme of PRT chemical modification with 7,10-Trioxa-1,13-
tridecanediamine. 
 
Several HPLC attempts were carried out to isolate the PRT modified species, 
even if unfortunately the adduct was unstable, since its degradation occurred 
during the first 36 h. On this basis, a change in the immobilization procedure 
was needed, and consequently PRT was put in reaction directly with the beads 
already modified with the spacer.  
 
 
4.2.2 PRT on beads immobilization 
 
PRT on beads immobilization was carried out using the agarose Reacti-Gel 
(6X) beads previously reacted with 4,7,10-Trioxa-1,13-tridecanediamine 
(NH2-(PEG)2-NH2). A nucleophilic attack of the spacer terminal amino group 
onto the activated carbonyl function of the resin gave rise to the beads 





chemical modification (figure 37). A following Kaiser test was useful to 
demonstrate the presence of free NH2 function on the beads. The experimental 
conditions such as pH, temperature and amount of linker (see Material and 





Fig. 37. Reaction Scheme of Perthamide immobilization on beads. 
 
In the second step PRT was treated with the spacer-bearing matrix beads, and, 
as reported in figure 37, PRT immobilization most likely occurred through a 
nucleophilyc attack of the matrix free NH2 groups onto the -sulfated (Asn) 
residue followed by urea loss, as previously reported.  
The immobilization yield was calculated by integration of RP-HPLC peaks of 
the free PRT before and after the reaction. The measure of peak area reduction 
after 16 h gave a 50% immobilization yield (figure 38).  




The experimental procedures, reported in the experimental section, were 
optimized to reach a final concentration of 0.9 μmol drug/mL resin. A sample 
of control matrix was prepared by reaction of the activated Reacti-Gel (6X) 




Fig. 38. Chromatographic profile of free PRT  after 0 and 16 h incubation with Reacti-Gel 
agarose matrix modified with  4,7,10-Trioxa-1,13-tridecanediamine. 
 
 
4.3 Affinity purification of Perthamide C partners 
 
Crude cell extracts of J774.1 cells were loaded on the PRT-bearing matrix, to 
promote the interaction between PRT and its partners in the cell lysate. To 
distinguish between specifically and non-specifically bound components,  the 
same amount of cell lysate was also incubated with a control matrix sample.  





After several washing steps needed to reduce the amount of non-specific 
adsorption, proteins tightly bound were eluted by treating the beads with SDS-
gel loading buffer. Finally, proteins eluted by PRT matrix and control beads 




  Fig. 39. Experimental workflow used to profile PRT C interactome. 
 
Since no differences were evident simply looking at the comassie stained 
bands, both gel lanes (from PRT-bearing beads and control) were cut in ten 
pieces and subjected to in situ trypsin digestion. The resulting peptides 
mixture were analyzed by mass spectrometry through nanoflow reversed-
phase HPLC MS/MS (figure 39). Doubly and triply charged peptide species 
were fragmented, and all the MS/MS spectra converted into a peak list using 




the ProteinLynx software. Finally, protein identification were achieved by 
submitting all peak lists  to a protein database search on SwissProt engine. 
 
 
4.4 PRT interactome identification 
 
Database search produced two list of identified proteins for both gel lanes 
(PRT-bearing and control matrix), that were compared to establish the PRT 
specific partners. As reported in the Venn diagram (figure 40), all proteins 
identified in three independent experiments were clustered to generate three 
lists of putative PRT interactors, following overlapped to give a significative 
set of PRT protein interactors. 
 
 
Fig. 40. Venn diagram showing the number of proteins identified in control and PRT based 
experiments. The overlapping of proteins identified only in PRT based experiments allow us 
to identify a smaller file of PRT interactors. 





Based on this results, Endoplasmin, also known as glucose regulated protein 
94 (GRP94) has been identified as PRT main partner. 
GRP94 is a constitutively expressed endoplasmic reticulum (ER) lumenal 
protein, that is up-regulated in response to cellular stress such as heat shock, 
oxidative stress or glucose depletion. 
 GRP94 is thought to play a key role in the translocation of protein to the ER, 
in their subsequent folding and assembly, and in regulating protein secretion. 
GRP94 plays a role also in antigen presentation, by accessing the endogenous 
pathway and eliciting specific cytotoxic lymphocyte T (CTL) responses to 
chaperone bound peptides, via the major histocompatibility complex (MHC) 
class I pathway. GRP94 is a member of the Hsp90 family of stress proteins 
and shares 50% sequence homology over its N-domains and complete 
conservation in its ligand binding domains with Hsp90, its cytosolic isoform. 
Both Hsp90 and GRP94 are calcium binding proteins, but, despite their 
homology, they differ in binding affinity with the regulatory ligand ATP and 
hydrolysis activity. GRP94 exists as a homodimer, and the two subunits 
interact at two distinct intermolecular sites, the C-terminal dimerization 
domains and the N-terminal, cross-interacting with the middle domain of the 
opposing subunits. Furthermore, GRP94 contains a carboxy terminal KDEL 




4.5 Grp94-Perthamide interaction: SPR 
 
Since GRP94 is involved in inflammation, cancer progression and immune 
system regulation, we decided to measure the interaction between PRT and 
GRP94, and to this end we evaluated the affinity and the binding specificity by 
surface plasmon resonance (SPR). 




All the SPR experiments were performed using a commercially available 
canine isoform of GRP94, sharing a high degree of homology with the murine 
and human enzyme. As reported in figure 41, the sequence alignment reveals 
that these proteins have almost the same aminoacid sequence, and thus, canine 
protein can be considered a confident model. 
 
 
Fig. 41. Sequence alignment of murine and canine GRP 94. 





SPR is an optical technique suitable for characterizing macromolecular 
interactions, based on the evanescent wave phenomenon, useful to measure 
changes in refractive index very close to a sensor surface. The binding 
between a compound in solution eluting on its partner immobilized on a sensor 
surface results in a change in the refractive index.  
The interaction is monitored in real time, and the amount of bound ligand and 
the rates of association and dissociation can be measured. Thus,  GRP94 was 
immobilized on a CM5 sensor chip and PRT was injected over at 
concentrations ranging from 0.5 to 5 M. In figure 42, the sensograms 
(association and dissociation SPR curves) obtained from the binding of PRT to 
GRP94 at two different concentrations are shown.   
As expected, the increase of response units (RU) in the association phase and 
the slope of the dissociation phase of the complex are clearly dependent on the 
analyte concentration. The analysis of the ascendant region of the sensograms 
gave the ka values, whereas kd of the complex  was evaluated on the basis of 
the time required to completely dissociate the complex and the slope of the 




Fig. 42. Sensograms obtained from the binding of PRT to GRP94 at two different 
concentrations (0.5 M blue curve and 1.0 M violet curve). 
The dissociation constant KD of the PRT-GRP94 complex, calculated using a 
1:1 Langmuir algorithm, was found to be 2.6 (±2.0) M. Moreover, the 
binding selectivity of PRT for GRP94 was assessed comparing the PRT 




response vs. bovine serum albumine (BSA). PRT was injected on a BSA-
modified sensor chip in the concentration range between 0.5-5 M, and 
produced a typical curve shape (red curve) corresponding to an absence of 




Fig. 43.  Sensograms obtained from the binding of PRT to GRP94 (gray curve) and to BSA 
(red curve) at the same concentration (5 M). 
 
 
4.6 Hsp82-Perthamide interaction by SPR 
 
Heat shock proteins (Hsps) are a class of functionally related proteins whose 
expression is increased when cells are exposed to elevated temperatures or 
other stress
[114]
. Moreover, intracellular heat shock proteins are highly 
expressed in cancerous cells and are essential to their survival. Considering the 
high homology occurring between GRP94 and Hsp90, we decided to test the 
binding affinity between PRT and Hsp82, the yeast Hsp90 homologue, by 
SPR.  As reported for GRP94, we  immobilized Hsp82 on a CM5 sensor chip. 
Then, PRT was injected over the enzyme-modified sensor chip in the 
concentrations range 0.5-5 M. The sensograms (figure 44) were analyzed, 
using a 1:1 Langmuir algorithm through the BiaEvaluation software. The 
curves reported in figure 44 don’t dissociate back to the baseline within a 





reasonable time frame, possibly as a result of a strong binding. As a matter of 
fact, the KD for the PRT-HSP82 adduct was estimated as 43.3 (±5.0) nM, 





Fig. 44. Sensograms obtained from the binding of PRT to Hsp82 at two different 
concentrations (0.5 M gray curve and 1.0 M blue curve). 
 
The ability of PRT to specifically bind the heat shock protein HSP90 opens the 
way to further investigation on the role of PRT in the modulation of the 
enzyme function in vitro and in vivo.   It is noteworthy that Hsp90 was not 
included in the final list of PRT partners in the chemical proteomics approach. 
However, as reported by Rix and Superti-Furga in 2009
[1]
, HSP90 is a 
‘frequent hitter protein’ which is usually identified both in the drug-bound and 
control beads proteins lists, due to its high abundance in biological samples 
and sufficient affinity for the matrix. On this basis, it is usually excluded from 
the list of the specifically bound partners, as in our case. However, SPR 
validation assays gave us the chance to measure the PRT affinity for Hsp 90 
homologue and to disclose this protein as a strong partner of our natural 
product. 















Collagen stimulation of platelets induces rapid spatial 
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Platelets are nuclear cells that play a key role in the control of haemostasis
[115-
117]
. In the non-activated and resting state platelets circulate freely in the blood. 
The primary function of platelets is to occlude arteries, thereby preventing 
excessive bleeding after injury. Under pathological conditions, the same 
mechanisms are responsible for occlusion of vital arteries at the site of 
ruptured atherosclerotic plaques. Ischemic occlusions can lead to myocardial 
infarction and stroke
[118, 119]
. In vivo, platelet activation can be triggered by a 
number of stimuli, such as collagen, ADP, thrombin and serotonin. Direct 
contact of collagen with the platelets leads to their activation
[120]
. Platelet 
surface receptors, such as the glycoprotein VI receptor complex (GPVI) and 
integrin 21,
[121]
 accommodate binding to collagen with consequent 
adhesion, aggregation, cytoskeletal reorganization and granule secretion of the 
platelets
[122]
. All the above-mentioned stimuli act through binding to specific 
membrane G-coupled receptors, which activate their down-stream intracellular 
signaling pathways. These tyrosine kinase mediated pathways are responsible 
for the observed initial physiological responses
[122, 123]
. In order to maintain 
intact healthy vessel physiology, a tight regulation of platelet functions and of 
all these intracellular pathways is required. In general, the actual view of how 
signaling pathways are regulated is shifted from a more linear controlled 
system to a dynamic and localized set of events, taking place in a complex 
network of proteins each having a specific function in time and space
[124]
. 
Spatio-temporal control of signaling proteins is an emerging concept that 
combines the omnipotency and high specificity of many signaling molecules 
and proteins, even within a single cell. A well-documented example of such a 
controlled system is the cAMP (3’-5’-cyclic-adenosine monophosphate) 
regulated signaling that is translated into very specific events at very specific 
loci within the cell
[125]
. 





The main target of cAMP is the cAMP-dependent protein kinase (PKA), 
which can interact with different members of the A-kinase associated proteins 
(AKAP) family to achieve spatial specificity. AKAPs physically localize 
PKA’s activity close to its substrates to avoid cross-reactivity of different PKA 
pathways
[126]
. Further specificity is achieved by generation of localized pools 
of cAMP that are generated close to the site of action and not throughout the 
whole cell
[127]
. These pools are spatially, but also time-wise controlled by 
phosphodiesterases (PDEs),
[127]
 that have been shown to co-localize with PKA 
at specific AKAPs. PDEs degrades cAMP
[128]
 to terminate signaling, and they 
are themselves dependent on phosphorylation by PKA
[129]
. Another layer of 
control is implemented by localization of specific phosphatases to AKAPs to 
also counteract PKA activity at the level of the substrate
[125]
. 
Dynamics in signaling complex constitution, through specific phosphorylation 
of AKAPs, seems a likely additional level of control. Such modifications 
could trigger binding/release of specific components in a similar manner as 
SH2/SH3 domains in tyrosine signaling. However, very few examples have 
emerged until now
[130]
. In a more specific context to this work, it has been 
shown that phosphorylation of the type IIa regulatory subunit of PKA (PKA-
RIIa) at Ser99 increases its affinity for AKAPs
[131]
, hinting at potential 
regulatory dynamics at the level of complex constitution. 
It is well known that high intracellular concentrations of cAMP, but also of 3’-
5’-cyclic-guanosine monophosphate (cGMP), interfere with the platelet 
activation pathways
[132]
, mainly through their kinases PKA and cGMP-
dependent protein kinase (PKG)
[132]
. cAMP and cGMP operate 
downstream
[128]
 of resting signals such as adenosine, ß-adrenergic signals, 
PGE1, PG-I2 and nitric oxide, respectively. Although characterized to a lesser 
extent, PKG is also found to localize to specific cellular compartments through 
interaction with G kinase associated proteins (GKAPs)
[133]
. How platelets 
engage in activation and how they respond at the level of cyclic nucleotide 




regulated proteins is currently not well understood, but very important to 









Large scale proteomics in combination with stable isotope based quantitation 
has emerged as an excellent tool to study temporal changes of signaling 
cascades, especially when focused on phosphorylation
[134, 135]
. However, the 
potential to look at protein-protein interaction dynamics has only marginally 
been exploited.  
To study cyclic nucleotide signaling, large-scale phosphoproteomics is not the 
method of choice as PKA and PKG, but especially their corresponding 





AKAPs are generally quite low abundant and therefore often missed in large-
scale studies
[136]
. In this field, we decided to zoom into the specific spatio-
temporal alterations of cyclic nucleotide regulated proteins in platelet 
activation. Thus, we applied a targeted quantitative chemical proteomics 
approach, using immobilized cAMP and cGMP beads, to specifically enrich 
this class of signaling proteins
[136, 137]
, and to evaluate the differential 
cAMP/cGMP-interactome of resting and (for 5 minutes) collagen stimulated 
platelets. Finally, we focus our attention on several (differential) protein 
phosphorylation events identified on our pulled down proteins, which can 
drive the spatial reorganization. 
 
 
5.2 Isolating Specific Proteins of Interest 
 
A quantitative chemical proteomics approach using dimethyl stable isotope 
labeling
[136, 137]
 was adapted to monitor downstream changes in cyclic 
nucleotide dependent proteins upon activation of platelets by collagen (figure 
45). CRP (collagen related peptide), a specific GPVI agonist, was used to 
stimulate the platelets, while parallel pathways were blocked (see 
experimental section).  
Differential quantitative pull downs were performed using platelets of five 
individual human donors, whereby each time CRP-activated (for 5 minutes) 
and resting platelets of the same donor were compared. After combining all 
acquired data, we compared this set of enriched proteins with a global 
unbiased inventory of the whole platelet proteome, allowing us to differentiate 
background from specific interacting proteins (see experimantal section). This 
resulted in a small but stringent core cAMP/cGMP interactome of proteins, 
whose the enrichment in the pull-down was at least 4-fold compared to the 
global platelet proteome.  






Fig. 46. Chemical proteomics strategy to enrich and differentially quantify pulled-down cyclic 
nucleotide signaling proteins and their interacting partners in resting and CRP stimulated 
platelets. Isolated platelets were divided in two 80 equal fractions and treated with CRP 
(active) or saline (resting). In parallel, lysis was performed and proteins were extracted prior 
to incubation with the immobilized cyclic nucleotide beads. cAMP/cGMP interacting core 
proteomes were subjected to an in solution digestion prior to stable isotope labeling with 
regular (light) and deutered (heavy) formaldehyde. Labeled peptides were mixed in a 1:1 total 
protein amount ratio followed by LC-MS/MS analysis for protein identification and 
quantitation. 
 
Fifteen proteins within this group have a well-documented connection to 
cAMP/cGMP signaling, such as several PKA’s, PKG’s, AKAPs, GKAPs and 





PDEs. The other twenty are putative interactome candidates. The differential 
abundances of these 35 proteins in the pull-downs from activated versus 




Tab. 2. Differential abundances of proteins from cAMP/cGMP signaling and putative 
cAMP/cGMP interactome  identified in the pull-downs from activated versus resting platelets. 
The values, reported ±st. dev, are the average of 5 individual experiments. 




5.3 Spatial reorganization occurring in signaling nodes upon collagen 
activation of platelets 
 
The primary interactors PKA-R and PKG Iß, exhibited a stimulated/resting 
abundance ratio of around 1.0 (0 on 2log10 scale, figure 47 A) in all donors, 
revealing that both their abundance and affinity to the beads is not altered 
upon stimulation. In contrast, the amount of PDE5A bound to the beads 
increased significantly (3.0-fold) upon CRP-activation, whereas the amount of 
PKG type II (PKG2) decreased slightly (ratio 0.7).  
This increased/decreased enrichment reflects more likely a change in affinity 
towards the beads or availability in the soluble proteome, as we assume that 
the amount of protein turn-over is negligible in the 5 minute time frame of 
activation. It is well documented that PDE5 affinity for cGMP increases upon 
phosphorylation at Ser102
[138]
, therefore we investigated the peptides 
identified for PDE5A for presence of this modification, but we were unable to 
observe this specific site. However, in PDE5A, Ser92 was increasingly 
phosphorylated (data not shown) in activated platelets, and may thus also 
plays a role in the observed increased affinity of PDE5 for cGMP in stimulated 
platelets. PDE2, another member of the PDE-family captured in our 
experiments, displayed no differential affinity in activated platelets (figure 47 
A). 
Next to primary interactors (PKA-R, PKG, PDEs) our approach allowed us to 
simultaneously monitor the differential association of several known 
secondary interactors (PKA-C, AKAPs, GKAPs) to the pool of primary 
interactors. It is well documented that overall cAMP levels and hence overall 
PKA activity diminish upon platelet activation
[139]
. This is in agreement with 
our findings that upon CRP-stimulation the association of the PKA catalytic 
subunits PKA-C and PKACß to PKA-R is increased (2.2-fold and 1.8-fold, 
figure 47 B).  







Fig. 47. Differential affinity analysis upon CRP induced platelet activation. (A) Differential 
enrichment ratios (Logscale) of cAMP and cGMP primary interactors. (B) Differential 
enrichment ratios of secondary interactors. The used colors represent different categories; 
PKA catalytic subunits (white), AKAPs (yellow), PKG interactors (blue). Ratios are 
normalized versus the ratio of their corresponding primary binders (Tab. 2). Significant 
changes are marked with a * for p<0.05 and ** for p<0.01. 
 
Increased formation of holo-enzyme leads to reduced kinase activity
[140]
. A 
different set of secondary interactors are the AKAPs and GKAPs. Enrichment 
changes observed for these proteins reflect altered composition of the various 
signaling scaffolds in activated platelets. As illustrated in figure 47 B, binding 
of AKAP9 and AKAP2 increased significantly upon activation, whereas 
association to AKAP7 remained unaltered. Some other AKAPs also showed 




increased binding, however, these could not be significantly quantified in all 




Tab. 3. The AKAPs reported in the table showed increased binding upon CRP treatment. 
These proteins, due to their low abundance, were not quantified in all five donors. 
 
In platelets, the inositol-1,4,5-trisphosphate receptor–associated PKG substrate 
(IRAG, MRVI1) is assembled in a macromolecular complex together with 
PKG Iß and the inositol-1,4,5-trisphosphate receptor type I (IP3RI)
[141]
. 
Although known to be quite low abundant, we were able to detect all known 
components of this macro-molecular scaffold complex, following capture of 
the PKG Iß primary interactor. Interestingly, the association of this 
PKG/IRAG/IP3R signaling scaffold increased by over 2-fold upon CRP 
stimulation (IRAG 2.1-fold, IP3R1 2.8-fold, figure 47 B), although the 
primary interactor PKG Iß displayed no changes. Interestingly, also IP3R type 
2 (IP3R2) showed the same differential enrichment as IP3R1. 
Other proteins in the core proteome of 35 pulled-down proteins have, at 
present, little known biological connection to the cAMP/cGMP primary 
interactors (table 2, putative cAMP/cGMP interactome). These are potential 




, their involvement in different biological 
pathways and molecular functions could be divided into several subsets. 
(figure 48). Among them, there is a receptor (Cationdependent mannose-6-





phosphate receptor (M6PR), also referred to as the IGF-II receptor), a Ca
2+
 ion 
channel (ATP2C1) and several cell-junction/cell adhesion proteins such as 
TGFB1I1 (Hic5)
[144]
, which is the platelet alternative for paxilin, and Galectin 














Fig 48. Proteins interaction network obtained using STRING (http://string-db.org/). Proteins 
with or without an evident biological connection to the cAMP/cGMP system  were submitted 
to STRING to better understand their biological interactions. In the network, links between 
proteins signify the various interaction data supporting the network, colored by evidence type 
as outlined in STRING. 
 
 
5.4 Differential phosphorylation occurring in signaling nodes upon 
collagen activation of platelets 
 
Crucial steps of platelet resting are regulated by phosphorylation events, many 
of them mediated by PKA and PKG, which can also be subjected to 
phosphorylation themselves.  





Tab. 4. Differential abundance of phosphorylation sites on cyclic nucleotide based signaling 
proteins before and after CRP stimulation. The active versus resting ratio for each observed 
phosphorylation is given including their standard deviations and amount of peptides observed. 
These ratios were normalized against the observed protein ratios (based on detected non-
modified peptides, supplemental table 3). T-tests for significance of change were performed 
by comparing the phosphorylation site ratios with the protein ratios. The maximum PTM score 





Although we did not specifically enrich for phosphoproteins or 
phosphopeptides, we were able in our experiments to identify and 
differentially quantify 14 different phosphopeptides (table 4), representing 9 
different phosphorylation sites (table 4). Although this number is relatively 
low compared to high-throughput phosphoproteomics datasets, it should be 
noted that several proteins we detected are novel, likely due to the strong 
enrichment of very low abundant signaling proteins. The differential extent of 
phosphorylation was calculated following normalization to their protein ratio 
(based on all non-phosphorylated peptides). We observed that PKA-RII was 
up-phosphorylated at Ser99, while PKG I showed a decreased 
phosphorylation at Ser63 upon CRP stimulation as illustrated by the mass 
spectra displayed in figure 49.  
































Fig. 49.  PKG Iß phosphorylation at Ser63 is reduced upon platelet activation with CRP (A) 
Dimethylated peak pair of the phosphorylated PKGI_ peptide QpSASTLQGEPR (left) and of 
the non-phosphorylated PKG Iß peptide AYEDAEAK 5 (right). Extracted ion chromatograms 
of the phosphopeptide QpSASTLQGEPR compared with a non-phosphorylated peptide of 
PKGIß (AYEDAEAK). (B) The corresponding extracted ion chromatograms of this peptide 
show a ~50% decrease in phosphorylation of the QpSASTLQGEPR (C) The tandem mass 
spectrum of the phosphopeptide unambiguously identifies Ser63 to be the site of modification. 




Also several, either reported or novel, phosphorylation sites on IRAG were 
detected, and did not change upon CRP stimulus, except S670 wherefore the 
phosphorylation decreased by about 60% upon activation. 
 
 
5.5 Spatial alterations in specific signaling nodes 
 
cAMP and cGMP and their respective kinases are heavily involved in platelet 
homeostasis, however their localized nature in platelets has not been 
investigated. Our quantitative chemical proteomic approach was used here to 
characterize the dynamic nature of the cAMP/cGMP core interaction proteome 
in resting versus activated platelets to reveal how the cyclic nucleotide system 
adapts to this transformation. 
Up to now, this was only addressed at the level of cAMP and cGMP 
concentrations and PKA/PKG activity
[132]
 (that was observed to decrease upon 
stimulus); however the downstream effects of this have not been addressed 
previously. Our data show that the constitution of several signaling complexes 
changes already significantly and rapidly within the 5 minute stimulation time 
window. In other words, upon platelet stimulus, PKA and PKG rearrange in 
different signaling complexes of which details are shown in figure 50 that will 
be further discussed below. 
 
 
5.6 Alterations in cGMP/PKG signaling nodes 
 
We identified two isoforms of PKG in human platelets; PKGIand PKG2. 
The former is a well documented isoform in platelets, whereas the latter has no 
prior functional annotation in platelets.  





The IP3RI receptor regulates IP3 mediated release of Ca
2+
 from intracellular 
stores, an important process in platelet activation
[146]
. PKG I inhibits this 
process through phosphorylation of IRAG at S657 and S670 (Uniprot sites on 



















Fig. 50. Summary of the observed alterations in the PKA and PKG signaling scaffolds upon 
CRP induced platelet activation. Depicted is the STRING network (http://string.embl.org), 
evidence view. The thicker blue lines represent more robustly documented interactions of the 
core cAMP/cGMP platelet interactome. Boxed proteins are primary cAMP/cGMP-bead 
interactors, non-boxed proteins are secondary interactors. Red arrows indicate overall decrease 
in protein capture, green arrows indicate increase, horizontal red and green indicates unaltered 
enrichment after 5 minutes stimulation of platelets. Increased capture of secondary interactors 
indicates dynamic rearrangements of PKA/PKG signaling scaffolds. 
 
We now show that upon platelet activation by collagen, the activity of this 
protein complex is affected at several levels of organization simultaneously. 




First of all, the activity of PKGI itself is reduced due to the observed reduced 
autophosphorylation at Ser63. Phosphorylation at this site is a measure of 
PKG’s basal activity which renders it less dependent on cGMP
[147]
.  
As expected, we observed that Thr530 in the catalytic cleft of PKG I is 
constitutively phosphorylated
[148]
. Second, phosphorylation of IRAG at S670 
was found to be reduced by 60%. This fits well with the observation by Antl et 
al. who showed that exogenous stimulus of platelets with cGMP or nitric 
oxide (induces resting) increased PKG-mediated phosphorylation at this 
site
[141]
. Both these decreased phosphorylation events will reduce activity of 
the PKG/IRAG couple and hence likely increase IP3-mediated Ca
2+
 release 
through the IP3RI to drive platelet activation. Antl et al. also showed that a 
small fraction of the total platelet PDE5 population is present in this complex 
and that only this portion of PDE5 is increasingly phosphorylated at 
Ser102
[141, 149]
 upon platelet stimulus, likely to reduce local cGMP 
concentrations more actively, thereby increasing IP3RI activity. Although we 
were unable to detect phosphorylated Ser102, we did observe Ser92 to be 
increasingly phosphorylated in a highly substoichiometric amount upon 
activation. This suggests that also Ser92 may be involved in this process.  
An intriguing observation is the general enlarge in enrichment of this intact 
scaffold complex following platelet activation, indicating increased tightness 
of the complex, possibly regulated by differential phosphorylation or other 
post-translational modifications. It seems there is a feedback mechanism in 
place here: Platelet activation leads to a decrease of PKG and IRAG activity, 
but to an increase in PKG/PDE5 localization to IRAG, probably to 
accommodate a rapid and efficient blockade of Ca
2+
 release from IP3R in case 
cGMP levels rise again. The cAMP/cGMP second messenger levels are 
regulated in space and time by a balance in production and degradation, 
catalyzed by localized PDEs. The major PDEs in platelets are thought to be 
PDE2 (hydrolyzes cAMP and cGMP, directly activated by cGMP), PDE3 





(hydrolyzes cAMP and cGMP and is activated by PKA) and PDE5 
(hydrolyzes cGMP and is activated directly by cGMP and by PKG)
[132]
.  
In this study, PDE5 is clearly the most dominant PDE, although PDE2 was 
also detected. PDE3 was not detected which may be due to the specific 
utilized capturing compounds, and/or its membrane localization properties. 
Upon CRP stimulation, we observed that the amount of captured PDE5 
increased significantly whereas the level of PDE2 remained constant.  
The increased affinity could be mediated by Ser92/Ser102 phosphorylation, 
however these phosphorylations can only occur to the small fraction of PDE5 
that is localized to the IRAG/IP3RI complex (~1-2% at best)
[141]
 and would 
not explain the overall increase of 3-fold in the total PDE5 pool. An 
alternative explanation may rise from the possibility that more PDE5 becomes 




5.7 Alterations in cAMP/PKA signaling nodes 
 
In general, activation of platelets leads to reduced cAMP levels through an 
inhibitory G-protein coupled receptor mediated inhibition of cAMP production 
by adenylate cyclase
[132]
. A reduction in cAMP concentration then leads to 
dissociation of it from PKA-R and increased PKA-R/PKA-C holoenzyme 
formation. There are four distinct genetic isoforms of PKA-R. Our data reveal 
that based on spectral counts
[137]
, PKA-RI, RIIand RII constitute the 
major isoforms in platelets, whereas PKA-RI seems under-represented. We 
identified 7 AKAPs in platelets, whereby AKAP9, AKAP7 and AKAP2 were 
most abundant, although AKAP1, AKAP10, AKAP11 and MAP2 were also 
detected. Interestingly, similarly to PKG/IRAG, stimulation of platelets seems 
to lead to tighter association of PKA with certain AKAPs. 




Our data reveal that collagen activation diminishes overall PKA activity as 
measured by the increase in pulled down holo-enzyme. Several 
phosphorylation sites were observed on PKA-R proteins (table 4), of which 
Ser99 of PKA-RII was the only one detected that changed upon collagen 
stimulation. 
Recently, in the rat neonatal cardiomyocyte context
[131]
, a higher level of this 
phosphorylation site was linked to a decreased affinity for PKA-C and thus 
higher activity of PKA, which contradicts the view of PKA being less active in 
activated platelets. Also, increased phosphorylation of Ser99 increases the 
affinity of PKA-RII for AKAPs both in vitro and in vivo
[131]
, in line with 
what we observe here since AKAP9 is a known PKA-RII interacting 
AKAP
[136]
. In the same model, this increased AKAP interaction of PKA-RII 
leads to increased phosphorylation levels of the nearby substrates 
phospholamban and the ryanodine receptor through interaction with 
AKAP15/18 to ultimately increase the contractile Ca
2+
 response in these 
cells
[131]
. In platelets, increased phosphorylation could accommodate the 
observed increased calcium release upon activation, albeit not through AKAP7 
and the ryanodine receptor, but perhaps through AKAP9 and IP3R, which 
have recently been reported to interact in cerebellar granule cells
[150]
. This 
would mean that one, or more, specifically localized pools of PKA-RII have 
a stimulatory effect on platelet activation, rather than on resting. This enforces 
the idea that different spatio-temporally controlled pools of cyclic nucleotide 
based signaling proteins have different functions. 
Altogether, our quantitative chemical proteomics approach to monitor collagen 
stimulation of platelets presents a detailed characterization of the cyclic 
nucleotide signaling proteins that play a role in the platelet activation 
response. The role of the PKG/IRAG/IP3RI complex, but also that of PKA-C 
in platelet activation, is recapitulated here and validates our approach. We 
show that the constitution of several signaling scaffolds is highly dynamic 





upon activation in platelets. This suggests that PKA and PKG relocation is 
important to accommodate the required intracellular changes induced by 
external signals. This interesting novel concept deserves extensive in-depth 
analysis at individual scaffold levels in the future, including the analysis of 




































































The target discovery of bioactive molecules endowed with intriguing 
pharmacological profiles is one of the main issues in the field of 
pharmaceutical sciences, since this is needed for a rational development of 
potential drugs. Indeed, a comprehensive characterization of a small molecule 
interaction profile inside a complex mixture, such as a cell environment, is 
necessary for a better comprehension of its poly-pharmacological activities 
and toxicities
[2]
. Moreover, the identification of the interactome of a potential 
drug needs a validation through biological evaluations, in which the role of the 
bioactive compound towards the identified target proteins has to be revealed 
and measured. Recent technological developments in the field of analytical 
methods, mainly mass spectrometry and liquid chromatography, gave and are 
still giving a significant improvement in the target discovery studies. In 
particular, mass spectrometry-based chemical proteomics is emerging as a 
powerful tool for a comprehensive characterization of a drug interactome, 
under physiological relevant conditions. Besides, even when the target of a 
drug is already known, information about the off-target activities are needed 
for a comprehensive evaluation of potential side effects and toxicities. Indeed, 
a drug hitting multiple targets can be applied in the therapy of several 
unrelated diseases or to increase its efficacy for a complex therapeutic 
application. On the other side, the modulation of multiple targets can also 
cause harmful drug side effects, which could be compensated, once known, by 
extra therapies or dose tuning.  
 
In this appealing scenario, I have optimized a strategy focused on chemical 
proteomics-based target discovery of three marine metabolites, namely 
Petrosaspongiolide M (PM), Bolinaquinone (BLQ) and Perthamide C (PRT 
C), all showing relevant anti-inflammatory properties. Since their 






inhibition, a full investigation of their interactome is of a broad interest to 
better understand the mechanism of action and the comprehensive  effect on a 
living cell. The application of this method allowed us to successfully discover 
the interactome of the above mentioned marine bioactive metabolites.  
 
The γ-hydroxy-butenolide terpenoid PM have been subjected, in the past, to a 
detailed in vitro
[55]
 and in vivo
[56]
 pharmacological investigation. It was found 
to inhibit human synovial PLA2  with IC50 of 0.8 M
[54]
, and to reduce the 
levels of prostaglandin E2, tumor necrosis factor  , and leucotriene B4 in a 
dose-dependent fashion
[55,56]
. In addition, an in-depth pharmacological 
investigation revealed its interference with the NF-kB pathway, with a 
consequent decrease of NF-kB–DNA binding
[56]
. Since the NF-kB pathway 
plays a crucial role in the development of the inflammation response, it was 
desirable to identify the specific target modulated by PM, representing a  
potential therapeutic target. The proteasome complex has been established as 
the primary cytoplasmatic target of PM. This evidence has been also validated 
by SPR and both in vitro and in cell assays. SPR data gave equilibrium 
binding constants (KD) (PM–proteasome) of 8 (±3.1), and 0.7 (±1.1) nM for 
the 20S proteasome and its PA28 complex, respectively, confirming a strong 
affinity between the ligand and its partner. Then, in vitro and in cell 
fluorescence experiments showed a relevant blocking of the proteasome 
activity by PM. 
More in details, PM was able to inhibit caspase- and chimotrypsin-like activity 
with an IC50 of 0.85 (±0.15) M and 0.64 (±0.11) M, respectively, while the 
trypsin-like activity of the proteasome resulted to be increased. This is not 
surprising, since this effect has been already reported for several inhibitors of 
caspase-like sites which allosterically stimulates the trypsin-like activity
[87]
. 









The same approach has been used to determine the interacting partners of 
BLQ, a marine hydroquinone isolated from the marine sponge Dysidea sp. 
BLQ was extensively studied as anti-inflammatory compound, indeed its 
PLA2-inhibition properties
[96, 97]
 and anti-inflammatory pharmacological 
profile were thoroughly examined, both in vitro and in vivo
[57]
. In particular, 
BLQ is able to reduce the production of mediators in acute and chronic 
inflammation, and is a modulator of the oxidative stress parameters in 2,4,6-
trinitrobenzenesulphonicacid (TNBS)-induced colitis in mice 
[55]
. Moreover, as 
reported by Busserolles and co-workers, BLQ dramatically reduces 
nitrotyrosine immuno-detection and colonic superoxide anion production, and 
decreases apoptosis, suggesting a potential protective action in intestinal 
inflammatory diseases
[55]
. Due to this wide anti-inflammatory profile, BLQ 
represented a good candidate for a target discovery-oriented chemical 
proteomics study. In this case, a so-called ‘off-target’ partner has been found, 
since clathrin was detected as major specific BLQ target
[152]
. The high affinity 
showed by BLQ versus clathrin was also proved through serial affinity 
chromatography approaches, opening the way to further investigation on the 
role of BLQ in the cellular uptake processes. Clathrin is a main component of 
the coated vesicles responsible for receptor-mediated endocytosis at the 
plasma membrane and for the receptor-mediated sorting of lysosomal enzyme. 
Clathrin-mediated endocytosis plays an important role in the selective uptake 
of proteins, viruses and other biologically important macromolecules at the 
plasma membrane of eukaryotic cells.Therefore, its modulating agents are 
considered significant targets for bio-pharmacological studies. To verify the 
biological relevance of BLQ towards the clathrin-mediated endocytosis, we 
studied the clathrin-dependent internalization of albumin by means of 
fluorimetric assays. The cytofluorimetric and microscopy analysis performed 
using a fluorescence-tagged BSA let us to measure the ability of BLQ to 






BLQ can be considered a good candidate as  new biotechnological tool with a 
novel chemical scaffold for the investigation of cell endocytosis processes.  
 
Pertamide C is a cyclic peptide isolated from the sponge Theonella 
swinhoei
[110]
, containing both natural and un-natural aminoacids, and it has 
been subjected to an in vivo investigation to test its anti-proliferative and anti-
inflammatory activities. PRT C did not show cytotoxic activity on KB cell line 
up to a dose of 10 mg/mL, whereas it is able to significantly reduce 
carrageenan-induced paw oedema both in the early phase (0–6 h) and in the 
late phase (24–96 h). Moreover, PRT C showed a dose dependent anti-
inflammatory profile which lead to a 60% reduction of the oedema, in mice, 
when administered at 300 g/Kg
[110]
. When compared with naproxen anti-
inflammatory profile (ED50 40 mg/kg), PRT resulted about 100 times more 
potent.  
Since an anti-inflammatory activity in the field of marine cyclic peptides is not 
common, with the exception of cyclomarins, salinamides and halipeptins, PRT 
C has been worthy of further investigations about the origin of its activity. A 
comprehensive characterization of PRT C interactome has been performed by 
chemical proteomics, revealing endoplasmin, the glucose regulated protein 94 
(GRP94), as the major partners of PRT C (unpublished data). The affinity 
between PRT C and its partner has also been tested by SPR experiments, 
measuring a KD of 2.5 μM (±2.1). 
GRP 94 is an endoplasmic reticulum (ER) lumenal protein  up-regulated in 
response to cellular stress such as heat shock, oxidative stress or glucose 
depletion, which plays a key role in the translocation of proteins to the ER, in 
their folding, assembly and in regulation of protein secretion. In addition, we 
tested the ability of PRT to bind another protein chaperone, called Hsp82, the 
yeast homolog of Hsp90. It has to be noted that Hsp90 was not included in the 






since, due to its high abundance, was identified as a matrix interactor. 
However, the SPR validation assays gave us the chance of measure PRT real 
affinity for Hsp 90 homolog and disclose this protein as an additional partner 
of our natural product. Indeed,  PRT strongly binds Hsp82 with a KD of 80.3 
(±5) nM, opening the way to further investigation on role of PRT in the 
modulation of heat shock protein function. 
 
A complementary point of view about the effect of a small bioactive molecule 
on cellular systems can be given by a quantitative chemical proteomics based 
approaches. On this basis, I employed this technique to discover the effect of 
collagen on platelet activation. Since cAMP and cGMP play a key role in 
platelet activation
[132]
, a combination of quantitative chemical proteomics 
approach with the specific enrichment of cAMP/cGMP signaling nodes has 
been performed
[135, 136]
, to investigate how cAMP-dependent protein kinases 
(PKA), and cGMP-dependent protein kinases (PKG) spatially reorganize in 
activated human platelets. 
Evaluating the differential cAMP/cGMP-interactome of resting and  collagen 
stimulated platelets of healthy human donors, I have revealed that both PKA 
and PKG significantly alter their intracellular localization, in particular,  
through attachement to different AKAPs and GKAPs. This evidence suggests 
that dynamic re-arrangement of these kinase scaffolds is a mean to adapt the 
system in response to the stimulus. Using protein phosphorylation data, 
several (differential) protein phosphorylation events were identified on our 
































































Chemical proteomics applied to Petrosaspongiolide M, 

















































Reacti-Gel (6X) CDI support was obtained from Pierce. The diamine linker 
(PEG, 4,7,10-trioxa-1,13-diamine) such asthe protease inhibitor cocktail were 
purchased from Sigma Aldrich. 20S Proteasome (human recombinant) and 
PA28 activator (human recombinant) were obtained from Boston Biochemical. 
All fluorogenic substrates (Suc-LLVY-amc, Boc-LRR-amc and Ac-GPLD-
amc) were purchased from Biomol International. 
 
 
7.1.2 Generation of a Functional Petrosaspongiolide M Affinity Matrix 
 
0.5 ml (dry volume) of the CDI activated Reacti-Gel (6X) beads was treated 
with 4,7,10-Trioxa-1,13-tridecanediamine (PEG) at 100 μM for 16 h at 25°C 
in NaHCO3 (10 mM) at pH 10. Then, the modified Reacti-Gel was washed 
three times with PBS and the presence of free amine groups on the modified 
Reacti-Gel surface was detected by Kaiser Test
[153]
. 
To obtain PM-fixed beads, the amine-beads were treated with 15 μmol of PM 
in 30% ACN/ 70% PBS at pH 10, and the mixture was kept for 16 h at 37 °C 
under continuous shaking.  
The amount of immobilized PM was calculated integrating the peaks relative 
to free PM after HPLC injections of supernatants at t = 0 h and t= 16 h using 
an Agilent 1100 Series chromatographer, on a Phenomenex C18 column (250 
x 2.0 mm) at a flow rate of 200 l/min. The gradient (Solution A: 0.1% TFA, 
solution B: 0.07% TFA, 5% H2O 95% ACN) started at 10% and ended at 95% 






Time %A %B 
0 90 10 
5 90 10 
15 5 95 
20 5 95 
 
Tab. 5. HPLC gradient used to quantify PM immobilization yield 
 
 
The imine bond occurred between PM aldehyde and free amine groups was 
reduced to amine with NaBH4 100 mM in sodium borate buffer (10 mM) at 
pH 8.5 for 30 min. The residual amino groups were blocked with 300 mM 
acetic anhydride dissolved in DMF at 10% TEA. 
To obtain the control matrix, the activated Reacti-Gel (6X) Support was mixed 
with PEG (100 μM) in PBS at pH 10 followed by the coupling with acetic 
anhydride. The matrices were stored at 4 °C. 
 
 
7.1.3 Purification of Cellular Petrosaspongiolide M Targets by Affinity 
Chromatography 
 
THP-1 monocytic cell line was cultured in RPMI medium (Sigma) 
supplemented with 10% (v/v) foetal bovine serum (Sigma), 100 U/ml 
penicillin and 100 μg/ml streptomycin (Sigma) at 37 °C in a 5% CO2 
atmosphere. THP-1 cell line was differentiated into a macrophage-like 




phenotype by incubation with phorbol-12-myristate-13-acetate (PMA). To 
induce an inflammatory response, bacterial lipopolysaccharides (LPS) were 
added to the culture medium at a final concentration of 100 g/ml for 24 h. 
Induced cells were scraped off and harvested by centrifugation at 4000g, 4°C 
for 10 min and immediately frozen. Cell pellets were lysed in PBS 1X (50 mM 
Natrium Phosphate, 150 mM Natrium chloride), 0.1% Igepal, supplemented 
with protease inhibitor cocktail and clarified by centrifugation 12000g, 4°C for 
20 min. Protein concentration was determined by Bradford assay 
[154, 155]
 and 
adjusted to 1 mg/ml. 
PM-fixed beads (50 l dry volume) and the control beads (50 l dry volume) 
were separately mixed with 500 μl of crude cell extract (1mg/ml) and 
incubated at 4°C for 16 h on a rotating wheel. After six washing with PBS, the 
bound proteins were eluted with SDS-PAGE sample buffer (60 mM Tris/HCl 
pH 6.8, 2% SDS, 0.001% Bromophenol blue, 10% Glicerol, 2% 2-
Mercaptoethanol), separated by electrophoresis and stained with Comassie 
brilliant blue G-250 Bio-Rad Laboratories
[156-158]
. 
Each lane of the SDS-PAGE separation was cut in 13 pieces. Gel pieces were 
subsequently washed with MilliQ Water and Acetonitrile and the proteins 
were digested in situ as described in Shevchenko protocol
[159]
. Briefly, gel 
slices were reduced in 1,4-dithiothreitol (10 mM) and alkylated with 
iodoacetamide (50 mM), then washed and rehydrated in trypsin solution (12 
ng/μL) on ice for 1h. After the addition of 30 μL ammonium bicarbonate (10 
mM, pH 7.5), samples were digested overnight at 25 °C. 5 μL of the obtained 
peptide mixture were injected onto a nano Acquity LC system (Waters Corp. 
Manchester, United Kingdom). 
The peptides were separated on a 1.7 μm BEH C-18 column (Waters Corp. 
Manchester, United Kingdom) at a flow rate of 200 nl/min. The gradient 
(Solution A: 0.1% formic acid, solution B: 0.1% formic acid, 100% ACN) 






acquired using a Q-TOF Premier mass spectrometer (Waters Corp., 




Fig. 51. Schematic rapresentation of Q-tof Premier mass spectrometer (Waters Corp., 
Micromass, Manchester, United Kingdom). 
 
Doubly and triply charged peptide-ions were automatically chosen by the 
MassLynx software and fragmented. MS data were automatically processed 
and peaklists for protein identifications by database searches were generated 
by the ProteinLynx software. Database searches were carried out with 
MASCOT server using the SwissProt protein database. The SwissProt human 
database (514212 sequences; 180900945 residues) was searched allowing 2 
missed cleavages, carbamidomethyl (C) as fixed modification, oxidation (M) 
and phosphorylation (ST) as variable modifications. The peptide tolerance was 
set to 80 ppm and the MS/MS tolerance to 0.8 Da. 
 
 
7.1.4 Cell Viability Assay 
 
Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay
[161]
. After PM treatment in a 




concentration range from 1 nM to 1000 nM, the mitochondrial-dependent 
reduction of 3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 




Fig. 52.  Mitochondrial-dependent reduction of 3-(4,5- dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) to formazan. 
 
 
7.1.5 In vitro Inhibition of 20S Proteasome Activity by Petrosaspongiolide 
M 
 
The fluorogenic peptides Suc-LLVY-amc (10 μM), Boc-LRR-amc (10 μM) 
and Ac-GPLD-amc (10 μM) were used to measure the chymotrypsin-like, 
trypsin-like and peptidylglutamyl hydrolyzing activities of the 20S 
proteasome, respectively. 
To increase the 20S proteasome activity, 0.1 μg of purified 20S proteasome 
was pre-incubated with PA28 activator (0.2 μg) for 15 min at 37 °C in 100 μl 
assay buffer (25 mM HEPES, 0.5 mM EDTA, pH 8.5). This step was followed 
by an additional incubation with either solvent (control) or PM at different 
concentrations ranging between 0.5-5 M at 37°C for 30 min. The reaction 






amino-4- methylcoumarin (amc) was monitored continuously (excitation, 380 




7.1.6 Cellular Inhibition of 26S Proteasome Activity by 
Petrosaspongiolide M 
 
The human monocytic cell line THP-1 was differentiated as described above 
and then incubated with 0.1, 0.5 and 1 M PM or 1 M MG132 for 24 h. As 
the small molecules were withdrawn from 100X stock solutions in Me2SO 
equal amounts of Me2SO were added to control samples. 
Cells were then scraped off and harvested by centrifugation. The cell pellets 
were incubated with lysis buffer (PBS 1X, 10% glycerol, 0.1% Igepal 
supplemented with a protease inhibitors cocktail) for 5 min on ice and 
sonicated for two pulses of 10 s, at 30% output power, using a Vibracell 
sonicator. Lysates were then centrifuged for 10 min at 10000g and 4 °C to 
remove cellular debris, and the protein concentration was determined 





7.2 Bolinaquinone target discovery 
 
7.2.1 Chemicals  
 
Reacti-Gel (6X) CDI support was obtained from Pierce. The linker 4,7,10-
trioxa-1,13-tridecanediamine (NH2-(PEG)2-NH2) and the protease inhibitor 
cocktail were purchased from Sigma Aldrich. The Trt-NH-(PEG)2-NH2  was 
from Merck. Chlorpromazine was from Sigma. Alexa Fluor 488 - Bovine 




serum albumin (BSA) conjugate was from Molecular Probes (Invitrogen 
detection technologies). THP1 cell line was from ATCC Cell Bank. 
 
 
7.2.2 BLQ chemical modification with 4,7,10-trioxa-1,13-
tridecanediamine 
 
10 mg of BLQ (25 mmol) were incubated with NH2-(PEG)2-NH2 (50 mM) in 
1 ml of NaHCO3 (10 mM) containing 40% of ACN.  The reaction mixture was 
maintained under shaking for 2h at 50°C. After the RP-HPLC fractionation, 
the mass spectrometry analysis was carried out on the major product of the 
reaction using a Q-TOF Premier Instrument (Waters, Manchester UK). The 
BLQ-NH-(PEG)2-NH2 adduct was purified using an Agilent 1100 Series 
chromatographer equipped with a Phenomenex C18 column (250 x 4.6 mm). 
The gradient (Solution A: 0.1% TFA, solution B: 0.07% TFA, 5% H2O 95% 




7.2.3 Generation of a Functional Boliquinone Affinity Matrix  
 
0.5 ml (dry volume) of the CDI activated Reacti-Gel (6X) beads were treated 
with 7.5 mg of BLQ-NH-(PEG)2-NH2 (13 mM) at 37 °C in NaHCO3 (10 mM) 
at pH 10. The mixture was maintained  under continuous shaking for 16 h. The 
amount of immobilized BLQ-NH-(PEG)2-NH2 was calculated integrating the 
peaks of the free BLQ-NH-(PEG)2-NH2 species after HPLC injections of 
supernatants at t = 0 h, t= 2h and t=16h, using an Agilent 1100 Series 
chromatographer. The HPLC runs were carried out onto a Phenomenex C18 






0.1% TFA, solution B: 0.07% TFA, 5% H2O 95% ACN) started at 10% and 
ended at 95% B after 15 min. The residual CDI groups were inactivated with 
100 mM ethanolamine dissolved in H2O. To obtain the control matrix, 
activated Reacti-Gel (6X) support was mixed with Trt-NH-(PEG)2-NH2  (100 
µM) in a buffer containing 10 mM NaHCO3 (pH 10) at 37 °C. The mixture 
was manteined under shaking for 4 h. The amount of immobilized Trt-NH-
(PEG)2-NH2 has been calculated as reported for BLQ (see before).  The 
matrices were stored at 4 °C. 
 
 
7.2.4 BLQ interactome identification by affinity chromatography and 
mass spectrometry 
 
THP-1 monocytic cell line were grown in RPMI medium (Sigma) 
supplemented with 10% (v/v) fetal bovine serum (Sigma), 100 U/ml penicillin 
and 100 µg/ml streptomycin (Sigma) at 37 °C in a 5% CO2 atmosphere. THP-
1 cell line was differentiated into a macrophage-like phenotype by incubation 
with phorbol-12-myristate-13-acetate (PMA). To induce an inflammatory 
response, bacterial lipopolysaccharides (LPS) were added to the culture 
medium at a final concentration of 100 g/ml for 24 h. The cells were washed 
once with phosphate-saline buffer (PBS), collected by centrifugation at 96 x g 
for 3 min. The obtained pellets were lysed in ice-cooled PBS 1X, 0.1% Igepal, 
supplemented with protease inhibitor cocktail. To remove cellular debris the 
cell suspension was centrifuged at 9617 x g for 10 min at 4°C. The supernatant 





and adjusted to 1 mg/ml. 50 μl of beads suspension of BLQ modified beads 
and the same amount of the control matrix were separately incubated with 500 
μg of THP1 total proteins under continuous shaking for 16 h at 4°C. The beads 
were precipitated by centrifugation (865 x g, 3 min, 4°C) and subjected to six 




washing with PBS. The bound proteins were eluted by boiling the beads in 30 
μl of SDS-PAGE sample buffer (60 mM Tris/HCl pH 6.8, 2% SDS, 0.001% 
Bromophenol blue, 10% glycerol, 2% 2-Mercaptoethanol) and subjected to 
SDS-PAGE separation at 12% of polyacrylamide. After gel electrophoresis, 
gels were subjected to colloidal Coomassie (Biorad G-250) staining
[156-158]
. 
The gel band  at an apparent MW of 190 kDa was cut out in both lanes. 
Briefly, gel pieces were washed with MilliQ water and AcN, reduced with 
DTT (10 mM) and alkylated with iodoacetamide reagent (54 mM). After few 
washing, pieces were incubated with 50 μl of trypsin (10 ng/μl) on ice for 1h. 
After the addition of 30 µL ammonium bicarbonate (10 mM, pH 7.5) samples 
were digested overnight at 37 °C
[159]
. The supernatant was collected and the 
peptides were extracted from the gel pieces by incubation with 100 μl of pure 
AcN. Finally, the supernatant was collected and both were combined. Each 
peptide mixture was dried out and dissolved in 10 μl of 10% formic acid. 5 μl, 
of the above mentioned peptides mixture, were injected onto a nano Acquity 
LC system (Waters Corp. Manchester, United Kingdom). The peptides were 
separated using a 1.7 µm BEH C-18 column (Waters Corp. Manchester, 
United Kingdom) at a flow rate of 400 nl/min. Peptide elution was achieved 
with a linear gradient from 15 to 60% B (Solution A: 0.1% formic acid, 
solution B: 0.1% formic acid, 100% ACN) in 55 min. MS and MS/MS data 
were acquired using a Q-TOF Premier mass spectrometer (Waters Corp., 
Micromass, Manchester, United Kingdom). Doubly and triply charged 
peptide-ions were automatically chosen by the MassLynx software and 
fragmented. After mass spectrometric measurements, data were automatically 
processed by ProteinLynx software to generate peak lists for protein 
identifications. Database searches were carried out with MASCOT server. The 
SwissProt database (release 57.13 of 19-Jan-2010, taxonomy Homo Sapiens, 
514212 sequences; 180900945 residues) was searched, allowing 2 missed 






and phosphorylation (ST) as variable modifications. The peptide tolerance was 
set to 80 ppm and the MS/MS tolerance to 0.8 Da. 
 
 
7.2.5 Serial affinity chromatography as a tool for identifying specific BLQ 
binding protein 
 
THP1 cells lysate (1.0 mg) was incubated with 50 ul of BLQ affinity beads for 
1h at 4 °C under continuously shaking. The supernatant obtained after beads 
precipitation (9617 x g, 2 min) was again incubated with freshly BLQ affinity 
beads at 4 °C, again for 1h. Then the new beads were precipitated (9617 x g, 2 
min) and the supernatant used for a third affinity purification step with BLQ 
affinity resin. The three batch of precipitated beads, obtained from serial 
affinity chromatography, were washed six times with PBS buffer and boiled in 
30 μl of SDS-PAGE sample buffer (60 mM Tris/HCl pH 6.8, 2% SDS, 
0.001% Bromophenol blue, 10% Glicerol, 2% 2-Mercaptoethanol). The 
proteins eluted were separated by SDS-PAGE at 8% of poly-acrylamide and 





7.2.6 Cell Viability Assay 
 
Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay
[161]
. Cells were seeded in 96-well 
microtiter plates in 100 l of growth medium.   
After 16 h incubation at 37 °C, cells were exposed to different concentration 
of BLQ, ranging from 0.01 μM to 100 μM, containing 1% DMSO. The same 
amount the of DMSO has been applied as control and the incubation was 
carried out for 48 h. The mitochondrial-dependent reduction of 3-(4,5-




dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to formazan 
was used to assess the possible BLQ cytotoxic effect. The experiment was 
carried out in triplicate and all the values were normalized to control.   
 
 
7.2.7 Uptake of FITC-labeled BSA by THP1 
 
THP1 (human acute monocytic leukemia cell line) were grown in RPMI 1640 
+ 10% FBS + 2mM L-Glutamine. The cells differentiated into macrophage-
like cell line after incubation with 161nM PMA (Phorbol 12-Myristate 13-
Acetate) for 72 hours. 5.0 x10
5
 THP1 differentiated cells were grown on 12 
well plates in presence of glass dishes. After removal of the culture medium, 
each dish was washed and pre-incubated with PBS buffer in the absence or 
presence of BLQ (50 μM and 100 μM in PBS from stock solution in DMSO) 
at 37°C for 10 min. A control experiment using  chlorpromazine (50 μM and 
100 μM in PBS from stock solution in DMSO), was performed in the same 
experimental condition. 
The cells were then incubated in presence of 20 g/ml AlexaFluor488-albumin 
(488-BSA) at 37°C for 1 hour. At the end of incubation, the uptake buffer was 
aspirated, and the dishes were rinsed rapidly three times with ice-cold PBS 
buffer.  
The cells were scraped with a rubber policeman in ice-cold buffer, washed by 
centrifugation at 4°C for 4 minutes at 1500 g and analyzed for internalized 
488-BSA by flow cytometry
[162]
. FACS analysis was carried out with a Becton 
Dickinson FACS Vantage flow cytometer (Becton Dickinson, Cowley, 
Oxford, United Kingdom). The excitation wavelength was 488 nm, and data 
were collected in FL-1 channel. For each analysis, 10000 events were 
recorded; data were analyzed with CellQuest software (Becton Dickinson, 








differentiated cells plated on glass dishes were incubated with 488-BSA in 
presence or absence of BLQ or chlorpromazine as described
34
. After 
incubation, cells were rinsed three times with PBS buffer and fixed with 3,7% 
formaldehyde in PBS. Uptake was analyzed with a Leica microscope AF-6000 
with a HCX PL FLUOTAR 63.0×1.25 oil objective. 
 
 




Reacti-Gel (6X) CDI support was obtained from Pierce. The linker 4,7,10-
trioxa-1,13-tridecanediamine (NH2-(PEG)2-NH2) and the protease inhibitor 
cocktail were purchased from Sigma Aldrich. The Trt-NH-(PEG)2-NH2  was 
from Merck. Biacore 3000, CM5 sensor chip, and coupling reagents (N-ethyl-
N’-(3-dimethylaminopropyl) carbodiimide (EDC), N-hydroxy-succinimmide 
(NHS), and ethanolamine-HCl) were purchased from GE Healthcare (United 
Kingdom). Endoplasmin (GRP94) was from Assay Design. 
 
 
7.3.2 PRT C reactivity profile 
  
100 mol of PRT were incubated with 500 mol of NH2-(PEG)2-NH2 in 200 
l of NaHCO3 (50 mM) containing 40% of ACN. The reaction mixture was 
incubated at 50°C and maintained under shaking (1250 rpm), using 
Termomixer eppendorf, for 16 h.  
5 l of the above reaction mixture were subjected to RP-HPLC fractionation 
and each chromatographic peak were analyzed by mass spectrometry using a 
LCQ-Deca instrument (Thermo Quest). 




The RP- HPLC analysis was carried out using an Agilent 1100 Series 
chromatographer equipped with a Phenomenex C18 column (250 x 2.0 mm). 
The gradient (Solution A: 0.1% TFA, solution B: 0.07% TFA, 5% H2O 95% 




7.3.3 Generation of a Perthamide Affinity Matrix 
 
0.2 ml (dry volume) of the CDI activated Reacti-Gel (6X) beads was treated 
with 5 mol of 4,7,10-Trioxa-1,13-tridecanediamine (TRT) dissolved in 
NaHCO3 (50 mM) supplemented with 30% ACN at pH 8.5 and incubated for 
16 h at 50°C under continuous shaking.  
Then, to prove the presence of free amine groups on the modified Reacti-Gel 




The obtained amine-beads were, then, treated with 3µmol of Perthamide (3 
mg) dissolved in 200 l of a phosphate buffer containing Na2HPO4 (10 mM), 
ACN 30% at pH 8.5. The reaction mixture was kept for 16 h at 50 °C under 
continuous shaking. The amount of immobilized PRT was estimated 
integrating the peaks of the free PRT species after HPLC injections of 
supernatants at t = 0 h, t= 2h and t=16h, using an Agilent 1100 Series 
chromatographer. HPLC runs were carried out using a Phenomenex C18 
column (250 x 2.0 mm) at a flow rate of 200 l/min. The gradient (Solution A: 
0.1% TFA, solution B: 0.07% TFA, 5% H2O 95% ACN) started at 10% and 
ended at 95% B after 20 min. 
The same experimental conditions were applied to the preparation of control 
matrix. Briefly, 200 l of  the activated Reacti-Gel (6X) Support were mixed 






pH 8.5. The HPLC runs, to estimate the yield of the immobilization reaction,  




7.3.4 Affinity purification of Perthamide C partners 
 
J774.1 murine macrophages cell line were grown in DMEM medium (Sigma) 
supplemented with 10% (v/v) foetal bovine serum (Sigma), 100 U/ml 
penicillin and 100 µg/ml streptomycin (Sigma), 4 mM Glutamine (Sigma), 10 
mM HEPES (Sigma), 10 mM Natrium Pyruvate (Sigma) at 37 °C in a 5% CO2 
atmosphere. The cells were collected by centrifugation at 96 x g for 3 min and 
washed once with phosphate-saline buffer (PBS, 50 mM Natrium Phosphate, 
150 mM Natrium chloride). The obtained pellet was dissolved in ice-cooled 
PBS 1X containing 0.1% Igepal and 5% glycerol and supplemented with 
protease inhibitor cocktail. 
The cells suspension were sonicated for 2 min with Vibracell (Sonics) setting 
an amplitude of  30% and clarified by centrifugation (9617 x g) for 10 min at 





 and adjusted to 1 mg/ml. 
50 μl of PRT beads suspension and the same amount of the control matrix 
were separately incubated with 1 mg of J774.1 total proteins under continuous 
shaking for 16 h at 4°C. The beads were precipitated by centrifugation (865 x 
g, 3 min, 4°C) and  washed six time with 5 mM Natrium Phosphate. The 
bound proteins were eluted by boiling the beads in 30 μl of SDS-PAGE 
sample buffer (60 mM Tris/HCl pH 6.8, 2% SDS, 0.001% Bromophenol blue, 
10% glycerol, 2% 2-Mercaptoethanol). The eleuted proteins were subjected to 
SDS-PAGE separation at 12% of polyacrylamide. After gel electrophoresis, 
gels were subjected to colloidal Coomassie (Biorad G-250) staining
[157, 158]
. 




The SDS-PAGE gel lane from control and PRT based experiment were cut in 
10 pieces. Each one was subsequently washed with MilliQ Water and 
Acetonitrile and subjected to in situ protein digestion as described in 
Shevchenko protocol
[159]
. Briefly, gel slices were reduced and alkylated using 
1,4-dithiothreitol (10 mM) and iodoacetamide (50 mM) respectively, then 
washed and  rehydrated in trypsin solution (12 ng/μL) on ice for 1h. 
After the addition of 30 μL ammonium bicarbonate (10 mM, pH 7.5), samples 
were digested overnight at 37 °C. The supernatant were collected and peptides 
were extracted by the gel slices using 100% ACN. Finally, the supernatant was 
collected and both were combined. All peptides sample were dried out and ri-
dissolved in 10% FA before mass spec analysis. 5 μL of the obtained peptide 
mixture were injected onto a nano Acquity LC system (Waters Corp. 
Manchester, United Kingdom). 
The peptides were separated using a 1.7 µm BEH C-18 column (Waters Corp. 
Manchester, United Kingdom) at a flow rate of 400 nl/min. Peptide elution 
was achieved with a linear gradient from 15 to 50% (solution A: 95% H2O, 
5%ACN, 0.1% FA; solution B: 95% ACN, 5% H2O, 0.1% FA) in 55 min.  
MS and MS/MS data were acquired using a Q-TOF Premier mass 
spectrometer (Waters Corp., Micromass, Manchester, United Kingdom). Four 
most intense doubly and triply charged peptide-ions were automatically 
chosen by the MassLynx software and fragmented. After mass spectrometric 
measurements, data were automatically processed by ProteinLynx software to 
generate peak lists for protein identifications. Database searches were carried 
out with MASCOT server. The SwissProt database (release 2010_11 of 02 
Nov 10, taxonomy Mus Musculus; 522019 sequences, 184241293 residues) 
was searched, allowing 2 missed cleavages, carbamidomethyl (C) as fixed 
modification o and oxidation (M) and phosphorylation (ST) as variable 
modifications. The peptide tolerance was set to 80 ppm and the MS/MS 






7.3.5 SPR analysis of PRT-GRP94/Hsp82 complex 
 
GRP94 was immobilized onto CM5 sensor chip using standard amine 
coupling procedures.
 
Phosphate–buffered saline, which consisted of 10 mM 
Na2HPO4 and 150 nM NaCl, pH 7.4, was used as running buffer. The 
carboxymethyl dextran surface was activated with a 5-min injection of a 1:1 
ratio of 100 mM EDC and 100 mM M NHS at 5 μl/min. GRP94 was diluted to 
a final concentration of 30 ng/l in 10 mM sodium acetate, pH 4.5 and 100 l 
prior the injection onto the activated chip surface at flow rate of 5 μl/min. 
Protein concentration was selected to obtain an optimal response (around 
13000 RU). Remaining active groups were blocked with a 7-min injection of 
1.0 M ethanolamine-HCl, pH 8.5, at 5 μl/min.  
PRT solution (0.5-5M),  used into the biosensor experiments, were diluted in 
10 mM phosphate saline buffer (pH 7.4) containing 2% DMSO. Each 




Fig. 53. Biacore 300 instrument, GE Healthcare (United Kingdom). 
 
Since the dissociated back to baseline within a reasonable time frame, no 
regeneration has been required. The interaction experiments were carried out 




at a flow rate of 10 μl/min, employing a 3 min injection time. The dissociation 
time was set at 600 seconds. Rate constants for association (ka) dissociation 
(kd) and the dissociation constant (KD) were obtained by globally fitting data 
from all the injection of different concentration of each compound, using the 
BIAevaluation software, using the simple 1:1 Langmuir binding model.  





















Collagen stimulation of platelets induces rapid spatial 
reorganizations in cAMP and cGMP signaling scaffolds 















































8-AHA-cAMP, 2-AHA-cGMP, Rp-8-AHA-cAMP, 8-AET-cGMP and 2-
AHA-cAMP agarose beads were purchased from BIOLOG (Bremen, 




Fig. 54. Chemical structure of cAMP and cGMP beads 
 
Protease inhibitor cocktail, complete mini, was from Roche Diagnostics, and 
phosphatase inhibitor cocktail was purchased from Sigma-Aldrich. 
Formaldehyde and isotope-labeled CD2O formaldehyde (20% solution in D2O) 
were also from Sigma-Aldrich. All the others chemicals (analysis grade) were 
purchased from commercial sources, unless stated otherwise. For all 
experiments high purity water, obtained from a Milli-Q system (Millipore, 
Bedford, MA), was used. 
 
 
8.2 Donors, Platelet isolation and CRP activation  
 
A total of 100 mL whole blood was drawn in citrate anticoagulated tubes to 






order to remove erythrocytes and leukocytes from the supernatant, resulting in 
platelets rich plasma. Blood platelets were separated from plasma by anther 
centrifugation step at 330 G for 10 min. The platelets were subsequently 
resuspended in Hepes Tyroid buffer, pH 6.5 + 10 ng/ml PGI2. After one wash 
step with Hepes Tyroid buffer, pH 9.0 + 10 ng/ml PGI2 followed by 
centrifugation at 330 G for 10 min, the pellet was resuspended in Hepes 
Tyroid buffer, pH 7.0 + 10 ng/ml PGI2 in a final concentration of 2* 10
11
 
platelets per liter. Platelets completely recover to the inactivated state by 
letting them rest for 30 minutes at room temperature. The “mean platelet 
volume” (MPV) was measured to exclude pre-activation of the platelets. 
Washed platelets were divided in two fractions. One of them was activated 
with the addition of 2.5 µg/mL Collagen Related Peptide (CRP), while HBS 
was added to the other fraction. After five minutes of incubation the solutions 
were centrifuged at 4000 g and the pellet was snap frozen in liquid nitrogen.  
 
 
8.3 Platelet lysis 
 
From each donor, the resting and CRP stimulated platelet samples were treated 
identically in parallel. The platelet fractions were taken up in 1.5 ml of ice-
cold lysis buffer containing 50 mM KH2PO4/K2HPO4-buffer, pH 7.0, with 150 
mM NaCl and 0.1% Tween 20 supplemented with protease (1 complete 
mini/15mL, Roche) and phosphatase inhibitor cocktail 2 (0.1%, Sigma-
Aldrich).  
Dounce homogenization was used for lysis. Cellular debris was removed by 
centrifugation in an eppendorf table top centrifuge at 10,000 rpm for 10 min at 
4°C. The supernatant was carefully collected and the pellet resuspended in 
lysis buffer (500 µl) to increase the yield of the lysis. The second supernatant, 
obtained by centrifugation (10,000 rpm, 10min, 4°C), was added  to the first 
one and the protein concentration was determined using a Bradford assay. 




From each different donor, between 3 and 4 mg total protein lysate per 100 
mL of whole blood was obtained. 
 
 
8.4 Pulldown Assay 
 
The pulldown experiment was carried out using a beads mixture composed of 
either four different immobilized cyclic nucleotides: 8-AHA-cAMP, Rp-8-
AHA-cAMP, 2-AHA-cAMP and 2-AHA-cGMP (1:1:1:1), or a two-bead 
mixture of 2-AHA-cGMP and 8-AET-cGMP (1:1). Three different methods 
were used in which the applied beads, but also the sample analysis strategy 
was varied. Method 1 (Experiment 1) uses a mix of the 4 different cyclic 
nucleotide beads in combination with off-line TiO2 based isolation of 
phosphopeptides. For method 2 (experiments 2 and 3) a 1:1 mixture of 2-AH-
cGMP and 8-AET-cGMP beads was used to focus on PKG based signaling 
proteins. Method 3 (experiments 4 and 5) was performed with the same set of 
4 beads as in method 1, but now strong cation exchange (SCX) of the eluted 
fraction was used to to analyze, and quantitate, more in depth the captured 
proteome. For both methods 2 and 3, 10mM ADP/GDP was added to compete 
for less specifically binding proteins as observed in experiment 1
[163, 164]
. Prior 
to pulldown the beads mixture was washed with 1mL of lysis buffer for each 
100µL of beads. After lysis, equal amounts of resting and activated platelet 
lysate were used. Prior to addition of the beads, the lysate was diluted to a 
final concentration of 2 mg/mL using lysis buffer. Depending on the yield of 
total protein from the isolated platelets, in each pull-down, 10µL of beads 
mixture was used per mg of protein. The obtained lysate-beads suspension was 
incubated for 2 h at 4°C by rotary shaking. The unbound fraction was removed 
and the beads were washed 6 times with 1 mL of lysis buffer. To further 
increase bead specificity, where applicable the first three washing steps were 








After washing, the bound proteins were eluted with 50 µl of 8 M urea in 
50mM of ammonium bicarbonate buffer (50mM, pH 8). The eluted proteins 
were digested with LysC (5 µg, Roche Diagnostics) for 4 h at 37 °C, reduced 
and alkylated  (10 mM DTT and 54 mM iodoacetamide) in 2 M urea and 




8.5 Stable Isotope Labeling Strategy 
 
The trypsin digested peptides were subjected to C18 (Sep-PAK, Waters 
Corporation) for desalting and subsequent on-column stable isotope dimethyl 
labeling as described previously
[165]
. Peptides coming from the resting 
platelets were labeled using “light” reagent (each N-terminus and lysine side 
chain will obtain two –CH3-groups) while, the peptides originating from the 
CRP induced platelets were labeled with “intermediate” reagent (two –CHD2 
added to each N-terminus and lysine side chain). After elution, the light and 
intermediate peptides were mixed in a 1:1 ratio, dried in vacuo and re-
suspended in 10% formic acid for mass spectrometric analysis. For the 
phospho-peptide analysis in method 1, the peptide mixture was subjected to 
TiO2 enrichment (Titansphere 5µM, GL science) using in-house packed micro 
columns. Briefly, the peptide mixture was loaded on the column pre-
equilibrated with buffer A (50% ACN, 5% FA), subjected to several washing 
steps with the same buffer before the elution of the phospho-peptides with 
buffer B (1.25% NH3, pH 10.5). The eluted peptide mixture was neutralized 





8.6 MS analysis and Quantitation  
 




LC-MS analysis was performed using an Agilent 1100 series liquid 
chromatography system equipped with an 20-mm Aqua C18 (Phenomenex, 
Torrance, CA) trapping column (packed in-house, i.d. 100 µm; resin 5 µm) 
and a 400 mm ReproSil-Pur C18-AQ analytical column (packed in-house, i.d. 
50 µm; resin 3 µm). Trapping was performed at 5 µl/min solution A (0.6% 
acetic acid) for 10 min. Peptide elution was achieved with a linear gradient 
from 13 to 32% of solution B (80% acetonitrile, 0.6%acetic acid) in 60 min at 
a flow rate of 100 nl/min obtained by passively splitting the flow from 0.6 
ml/min. 
Nanospray was achieved using a distally coated fused silica emitter (New 
Objective, Cambridge, MA; outer diameter 360 µm; i.d. 20 µm, tip i.d. 10 µm) 
biased to 1.8 kV. The LC system was coupled to a Finnigan Orbitrap 
Discovery mass spectrometer (Thermo Electron, Bremen, Germany). Briefly, 
the mass spectrometer was operated in the data-dependent mode to 
automatically switch between MS and MS/MS acquisition. Survey full scan 
MS spectra were acquired from m/z 350 to m/z 1500 in the OrbiTrap. The five 
most intense ions were fragmented in the linear ion trap using collisionally 
induced dissociation (CID) at a target value of 10,000.  
The obtained data was processed by Bioworks 3.3 (Thermo, Bremen, 
Germany) software to generate a txt file used for database searching with 
Mascot (version 2.1.0, Matrix Science, London, UK).  
 The SwissProt human database database 56.2 (398181 protein sequences; 
143572911 residues) was searched, allowing 2 missed cleavages, 
carbamidomethyl as fixed modification on cysteines, as well as “light” and 
“intermediate” di-methylation of peptide N termini and lysine residues and 
oxidation (M) and phosphorylation (ST) as variable modifications. The 
peptide tolerance was set to 15 ppm and the MS/MS tolerance to 0.9 Da. 
Proteins were organized using the Scaffold software package 
(Proteomesoftware). Quantification was performed using an in-house modified 
version of MSQuant
[167]






monoisotopic peaks of “light” and “intermediate” forms of the peptide were 
calculated and averaged over consecutive MS cycles for the duration of their 
respective LC-MS peaks in the total ion chromatogram using only MS scans; 
intermediate and light labeled peptides were found to co-elute. For 
comparison, all protein ratios were normalized. Initially normalization to the 
average ratio of PKA-Rs, PDE2, PKGIß and PKG2 was performed at 
individual experiment level. Subsequently, all secondary associating proteins 
(AKAPs, GKAPs etc) were normalized to their respective primary 
interactor(s) as reported by us previously
[168]
. Significance of difference was 
tested using a t-test between the obtained normalized ratios of different 
proteins. Molecular, biological and pathway analysis of enriched proteins was 





8.7 Data analysis 
 
Through the use of the three different methods in which the applied beads, but 
also the sample analysis strategy was varied, specific, less-specific and non-
specific interactors of cAMP could be evaluated. Spectral counting across 
methods was used to isolate the core-cAMP interactome in human platelets. 
Method 1 (Experiment 1) showed good coverage on primary interactors, 
however secondary interactors (AKAPs, GKAPs) were obscured by other 
nucleotide binding proteins such NDKB and LDHA and LDHB.  For both 
method 2 and 3, 10mM ADP/GDP was added to compete for less specifically 
binding proteins and increase coverage on secondary interactors. From all 
combined experiments, only proteins with a robust identification and specific 
enrichment rate were included based on the following criteria; (i) at least 10 
spectra summed over all experiments, (ii) identified in at least 3 out of 5 
experiments. In the remaining dataset, proteins specifically competed by 
ADP/GDP could be marked , as these had high spectral counts in Experiment 




1, but low, or no counts at all in the others. Also a set of proteins that seemed 
to have affinity for cAMP, but not cGMP could be annotated based on spectral 
count features (data not shown), meaning their enrichment is bead specific and 
not PKA/PKG-dependent, since these kinases bind to all four beads with 
~equal affinity. The remaining 35 proteins could be annotated as the core 
cAMP/cGMP interactome of human platelets and were further evaluated 
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